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ABSTRACT
Predictors of Cardiovascular and Gastrointestinal Disorders, Inappropriate Nonsteroidal Antiinflammatory Drug Use, and Alzheimer’s Disease and Related Dementia in Older Adults with
Osteoarthritis
Jayeshkumar Patel
Osteoarthritis (OA) is a degenerative arthritis affecting over 30 million Americans most of whom are over 65
years or older. Its clinical management is complicated by several disease- and treatment-specific factors. These
include the co-occurrence of cardiovascular and gastrointestinal disorders (CV-GID), the inappropriate use of
non-steroidal anti-inflammatory drugs (NSAID) to manage pain, and the risk of certain age-related chronic
conditions like Alzheimer’s disease and related dementia (ADRD). Moreover, older adults with OA are at a
higher risk of CV-GID, inappropriate NSAID use, and ADRD. Additionally, these factors can also affect one
another in both a positive and a negative way. For example, the long-term use of NSAID has been shown to
increase the risk for cardiovascular and gastrointestinal disorders. On the other hand, their use has been shown to
decrease the risk of ADRD in some studies. NSAID use is disproportionately higher among older adults, so the
benefits or risks associated with such use should be taken into account while making treatment decisions.
However, there is a gap in our understanding of the clinical and demographic factors that increase the risk of cooccurring CV-GID, inappropriate NSAID use, and ADRD in older adults with OA. This dissertation pursued
three related aims to fill this knowledge gap: 1) identify the leading predictors of CV-GID; 2) identify the
leading predictors of inappropriate NSAID use; and 3) examine whether duration of NSAID use is a leading
predictor of ADRD and how other factors affect this relationship using a combination of machine learning
techniques. All three aims used a retrospective, longitudinal, cohort study design using de-identified commercial
health insurance insurance claims data from Optum De-identified Clinformatics Data Mart for years 2015
through 2017. OA was identified from these data using a combination of International Classification of Disease
– 9th Revision and 10th Revision (ICD-9 and ICD-10) codes. Using a random forest classifier, we identified age,
cardiac arrhythmia, and the duration of opioid use to be the top three leading predictors of CV-GID in our study
cohort. In the second aim, we found that around 13% of older adults with OA were prescribe NSAIDs not in
accordance with their CV and GI risk profile (i.e. inappropriate NSAID use). Using an eXtreme Gradient
Boosting classifier and Shapley Additive eXplanations, we found durations of non-selective and selective
NSAID use to be the top two predictors of inappropriate NSAID use. Older adults with low CV and high GI or
high CV and low GI risk were also identified to be more likely to be treated with inappropriate NSAIDs. Lastly,
results from our third aim showed that duration of NSAID use was among the top five leading predictors of
ADRD in our study cohort. With the help of interpretable machine learning techniques, we found that the effect
of NSAID duration on ADRD varied by factors like age, gender, and OA-related pain. In summary, the results of
these aims suggest a need to target certain patient-level factors for better management of older adults with OA to
reduce their risk of CVGID, NSAID-related adverse events, and ADRD. The results from this dissertation also
highlight the need for further research to identify the causal links between the leading factors and the outcomes.
The clinical management of OA is complex, and the knowledge obtained from this dissertation could help ease
its burden for clinicians and patients.
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Chapter 1
1 Introduction
Epidemiology of Osteoarthritis
Osteoarthritis (OA), the most common form of arthritis, occurs due to the breakdown of the cartilage
surrounding joints.1,2 It starts gradually and worsens with time. Hence It is also known as degenerative or “wear
and tear” arthritis. Any joint in the body can be affected by OA, however the joints of knee, hip, and hands are
most commonly affected.1 There are two different classifications for OA based on how it is diagnosed. These
include radiographic or symptomatic OA. Radiographic OA is the most common and the gold standard method
for diagnosing OA.3 Based on the most common radiographic classification, OA is graded using the KellgrenLawrence (K/L) grading scheme.3 According to this scheme, is graded on a scale of 0 to 4, with a score of 0
indicating no OA, and 2 or more indicating a definite OA.4 Symptomatic OA is defined based on the presence of
certain symptoms (i.e. pain, aching, and joint stiffness) in addition to the radiological confirmation. The study of
people with symptomatic OA is considered more clinically relevant because not everyone with radiographic OA
have clinical disease.5 Moreover, the burden of OA as it relates to its treatment and the effect on quality of life
may be more severe in individuals with symptomatic OA.
The prevalence of OA also varies based on whether it is defined using the symptomatic or radiographical
classification. In general, the prevalence of symptomatic OA is much lower than that of the radiographic OA.
According to various estimates, the age-standardized prevalence of radiographic hip, knee, or hand OA is
approximately 27%.6 The age- and sex-standardized incidences of hip, knee, and hand OA have been reported to
be 88, 240, and 100 per 100,000 person-years, respectively.7 The risk factors for OA are well-known and the
disease is considered to be a product of an interplay of both systemic and local factors.6
Approximately 30 million adults in the United States (US) suffer from OA.6 This number is expected to
rise in the coming decades at the US population ages.6 OA can occur at any age, however, older adults (>65
years) are at a higher risk.8 Age is one of the strongest risk factors for any type of OA.2 The cumulative exposure
to various risk factors with age and age-related biologic changes are thought to be the reasons for the increased
risk of OA in older adults.6 Other risk factors for OA include female gender9, race6, genetics, congenital or
developmental conditions10,11 (e.g. slipped capital femoral epiphysis, Legg-Calvé-Perthes disease), diet12,13 (e.g.
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vitamin D deficiency, selenium deficiency), obesity2, joint trauma14, occupation requiring repetitive use of joints,
and overuse of joints through strenuous physical activity15.
Disease Burden of Osteoarthritis
OA is associated with substantial disease burden measured in terms of clinical, economic, and humanistic
perspectives.
Economic and Humanistic Burden
The direct costs associated with the medical treatment of OA have been estimated to be around $65 billion per
year.8,16 In fact, OA was found to be the 2nd most costly condition treated in inpatient settings in the US in 2013
accounting for 4.3% of all hospitalization costs that year.17,18 Additionally, the indirect costs related to OA are
estimated to be approximately $10.3 billion.17,18
The humanistic burden of OA is also substantial with studies reporting significantly lower health-related quality
of life in adults with OA.19,20
Clinical burden
The clinical burden of OA includes pain, functional limitations, and comorbidity burden.
Pain and Pain interference with normal activities: Pain is the defining feature of OA with most available
treatments aiming to relieve pain. Unlike other chronic pain conditions for which the underlying disease
typically heals or improves with therapies, disease-modifying treatments for OA are not available. Thus, chronic
pain afflicts a lot of patients suffering from OA. As many as 1 in 4 adults with OA experience severe joint pain,
defined as a score of >7 on the 10-point scale.21 The chronic pain also catalyzes the functional limitations in OA
patients. A recent study19 using data from a nationally representative sample of US households reported that pain
interfered with normal daily activities of approximately 40% of adults with OA. Moreover, pain is the prime
reason behind almost all of the hip and knee replacements which are two of the very costly surgical procedures.21
Functional Limitations: The functional limitations associated with OA are significant. Approximately 16% of all
disability is attributable to OA22, the fourth largest of any other chronic conditions.23 It is also reported that
adults with OA are at least twice as likely to have functional limitations compared to those without OA. 19 While
80% of all OA patients have some degree of limitation in performing daily activities, 25% cannot perform such
activities, and approximately 11% require help with personal care.1
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Comorbidity Burden (coexisting and incident): The prevalence of co-occurring conditions is higher among
adults with OA.24 Around 1/3rd of individuals with OA have 5 or more chronic conditions.8,16 Among the many
co-existing conditions, the cardiovascular disease and gastrointestinal disorders (CV-GID) require special
attention due to several reasons. First, both the risk and mortality of CVD are higher in individuals with OA.25–27
Second, OA and CV-GID share many risk factors including age, physical inactivity, other chronic conditions
like depression. Third, the medications (e.g. nonsteroidal anti-inflammatory drugs (NSAIDs), opioids) used to
control pain in patients with OA have been shown to be associated with many CV and GI adverse events
(AEs).28–30 While the risk factors for CVD and GID alone in other populations are known, the predictors of CVGID in older adults with OA are not known. Such knowledge can be helpful in identifying the modifiable risk
factors for targeted interventions.
Apart from the co-existing conditions, adults with OA are also at a higher risk for several other chronic
conditions including hypertension, CVD, depression, and Alzheimer’s disease and related dementia (ADRD)
due to a variety of factors.31,32 Evidence from multiple observational studies suggest that older adults are at a
higher risk for developing ADRD.33 Both OA and ADRD are chronic debilitating conditions with enormous
clinical, humanistic, and economic burden. Both conditions also share several risk factors including old age,
physical inactivity, obesity, hyperlipidemia, and CVD.33 While the exact relationship between OA and ADRD
remains unclear, several hypotheses have been put forth by researchers. The higher prevalence of certain risk
factors for ADRD in adults with OA have been suggested to be contributing factors to this relationship. Such
factors include depression, physical inactivity, and CVD.34 Moreover, higher levels of local inflammatory
cytokines like interleukin-1, tumor necrosis-alpha, and enzymes like cyclooxygenase enzyme-2 (COX-2) and
their effect on brain structure and function have also been proposed.35
Treatment of Osteoarthritis
Clinical guidelines recommend a combination of educational, behavioral, physical, psychosocial, and
pharmacological interventions for the treatment of OA.36,37 Some of the recommended non-pharmacological
treatments for OA include exercise, weight loss, self-efficacy and self-management programs, and the use of
knee braces.36 Other treatments like yoga, cognitive behavioral therapy, acupuncture, manual therapy, and
massage are also conditionally recommended for patients with knee or hip OA.36 Among the pharmacological
3

treatments, both topical and oral NSAIDs are strongly recommended for adults with any type of OA. The use of
intra-articular glucocorticoid injections is also strongly recommended for patients with knee and hip OA. Some
of the conditionally recommended pharmacological treatments options include opioids, acetaminophen,
duloxetine, colchicine, and vitamin D.36 It is important to note that various treatments for OA do not provide
cure or affect its progression.
Commonly Used Pain Medications for Pain Relief (NSAIDs and Opioids)
Among the pharmacological treatments, NSAIDs and opioids are the most commonly used for pain relief.
Approximately half of the adults with OA report receiving NSAIDs or opioids.38–40 With the opioid pandemic
and a growing sentiment against the long-term use of opioids for chronic non-cancer pain conditions,
increasingly more patients may rely on prescription NSAIDs for pain relief.
Harmful Effects of NSAIDs
However, the use of NSAIDs has also come under scanner for serious and potentially fatal CV and GI AEs. It is
estimated that each year more than 100,000 adults are hospitalized and over 16,000 die from NSAID-related
AEs in the US.41,42 To reduce the risk for NSAID-related GI and CV AEs, clinical guidelines recommend that
NSAIDs should be used for the shortest duration and at the lowest dose possible.36,37,43 As the risk of AEs is
different based on the type (selective vs no-selective) NSAID, the guidelines also recommend taking into
account the pre-existing risk factors to decide on the type and duration of NSAID use. Despite the guidelines and
recommendations, various studies have reported that inappropriate NSAID use is common among adults at risk
for CV and GI AEs.44,45 However, the prevalence of inappropriate NSAID use and their predictors among OA
patients in the US are not known.
Beneficial Effects of NSAIDs
Apart from being moderately effective in improving pain and functional outcomes in adults with OA, NSAIDs
have also been evaluated to reduce the risk of some other chronic conditions including ADRD.46 Recent
evidence suggests a link between chronic low inflammation seen in adults with OA and a higher risk for
ADRD.47 Apart from this, the direct inhibition of COX-2 and subsequent decrease in the levels of several of the
important substances involved in AD pathogenesis including prostaglandins, thromboxanes, and prostacyclins
have also been proposed to lower the risk for ADRD.35,48Thus, it has been proposed as well as well-studied that
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the anti-inflammatory properties of NSAIDs could also reduce the risk for ADRD. However, the evidence on
this relationship is unclear. While several studies found that NSAID use decrease the risk of ADRD46,49,50, some
other studies did not find any such association.51 It needs to be noted that these studies differed significantly in
their patient populations and their definitions of NSAID exposure. Moreover, these studies were not specific to
older adults with OA, a subgroup of patients at high risk for ADRD, and did evaluate heterogeneity of treatment
effects of NSAIDs in different subgroups of patients.
Despite these knowledge gaps, research on the predictors of inappropriate NSAIDs use, co-existing CV-GID,
and incident ADRD among older adults with OA is lacking. Two cross-sectional studies conducted in Europe
have documented that a majority of high-risk adults with OA were prescribed NSAIDs.44,45 Two other non-US
cross-sectional studies52,53 suggest that younger age and presence of other painful conditions were associated
with NSAID use in high-risk patients. However, the knowledge about other risk factors is lacking. Additionally,
while the clinical burden of CVD or GID in OA is well documented, the predictors of combined CV-GID in this
patient population is not known. The study of the relationship between NSAID use and ADRD risk can also
benefit from the identification of variable interactions and their combined effect on the risk of ADRD using
machine learning approaches.
Patient Population
Older Adults with OA
Older individuals in this age group have higher prevalence and associated burden of OA.2 In fact, OA is the
second the leading cause of disability among older adults in the US.22,54 Moreover, older adults are also at a
higher risk for CV-GID and ADRD. Approximately 40% of older adults suffer from CVD55 and around 35%
with ADRD.55 The use of NSAIDs is also higher among older adults despite old age being one of the risk factors
for NSAID-related GI and CV AEs.39,56,57 Each year, approximately 41,000 hospitalizations and 3,300 deaths are
estimated to be due to NSAID-related AEs.58 Given the susceptibility of this particular patient group to these
conditions, our study focused on only these individuals for all aims.
Specific Aims
To identify the leading predictors of and their association to CV-GID among older adults with OA using
interpretable machine learning techniques.
5

H1: Care fragmentation, co-existing physical and mental health conditions, and risk factors for CVD and GID
will be among the top 10 leading predictors of CV-GID.
To estimate the prevalence of inappropriate NSAID use and identify its leading predictors among older adults
with OA using data science approaches.
H2: Older adults at high risk for CV and GI risk, care fragmentation, opioid use, other pain medication use, and
baseline NSAID use will be among the top predictors of inappropriate NSAID use at follow-up.
To examine the role of NSAIDs use on incident ADRD risk older adults with OA using machine learning
techniques.
H3: Age, delirium, polypharmacy, OA-related pain, and NSAID use will be among the top predictors of ADRD
in older adults with OA.
Conceptual framework
For specific aims 1 and 3, we adapted the modified
Determinants of Health Outcomes and Chronic
Disease model (Figure 2).59
This model suggests that the risk of a disease (e.g.
ADRD) and related outcomes (healthcare use and
costs) are affected by several factors which can be
grouped in the following dimensions: 1) community
resources- e.g. geographical region, 2) access to care-

Figure 1.1 Determinants of Health Outcomes and
Chronic Disease Model

e.g. type of health insurance plan and co-pay, 3) health-related factors- e.g. comorbidities, type of OA, OArelated pain, obesity, substance use disorder, and other psychiatric disorders, 4) biological factors- e.g. age, sex,
and 5) treatment-related factors- e.g. pain-related treatment (opioid, NSAID, and others), polypharmacy,
duration of NSAID use, type of NSAID (selective vs non-selective), and dose of NSAID.
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For aim 2, we used the Model of
Healthcare Utilization based on the
Andersen and Aday’s conceptual
framework60 (Figure 2) to study
inappropriate NSAID use among OA
adults. This model has been used in many
Figure 1.2 Healthcare Utilization Model
studies with different health conditions to study healthcare utilization. According to this model, the use of
healthcare service (i.e. NSAID) is determined by three factors: predisposing factors, enabling factors, and need
factors. Predisposing factors are those which reflect an individual’s propensity to use health services. These
include factors like age, race/ethnicity, region, etc. Enabling factors are those which facilitate access to the
healthcare services. Examples of enabling factors include health insurance coverage and provider specialty.
Need factors are potential needs for health service use, for example presence of comorbidities, chronic pain, or
other pain medication use.
Data Source
Study samples for all aims were selected from a 10% random deidentified sample from approximately 47 million
individuals in the Optum De-identified Clinformatics® Data Mart (Optum).61 The deidentified Optum data
contain insurance claims records of beneficiaries from a large commercial health insurance provider in the US
along with patients with Medicare Advantage plans contains commercial and Medicare Advantage claims. The
data are geographically representative of the commercially insured US population. Comprehensive longitudinal
data on demographics, diagnoses, medications, and other medical services provided to insured individuals are
available in this database. Insurance claims from a combination of inpatient, outpatient, and pharmacy claims
from years 2014 through 2016 were used. As data are deidentified, informed consent from patients was waived.
International Classification of Diseases, 9th and 10th Revision (ICD-9 and ICD-10) codes, National Drug Codes
(NDC), revenue codes, and Healthcare Common Procedure Coding System (HCPCS) codes were used to
identify relevant clinical conditions, medications, services and procedures.

7

Analytical Approach
We used both statistical learning and machine learning approaches in our studies. We used frequency
and percentages to describe categorical variables and mean and standard deviations for continuous variables.
Generalized linear models (GLM) with appropriate binomial link were used to examine the association of key
independent variables to the dependent variables in our studies. These models adjusted for any relevant
confounders including but not limited to age, sex, region, type of insurance plan, specialist visit, substance use
disorder, obesity, hypertension, other chronic and pain conditions, OA-related pain, polypharmacy, opioid use,
type of NSAID, and use of other pain medications. Despite being the standard parametric method, logistic
regression can be used to create predictive models. However, it has been shown that logistic regression that uses
only statistical significance may not be the best predictive modeling methods.62 While logistic regression fits a
single line to divide the space into two exact regions, decision trees created from bootstrapped samples and
gradient boosted trees, bisect the space into smaller and smaller regions, thereby giving a higher predictive
accuracy.
Although machine learning (ML) methods have been in existence since 1950, their use has risen significantly
following the pioneering work by Breiman63. Many studies in health services and outcomes research have used
machine learning methods and have found it to be better than traditional statistical approaches in some cases.64–66
The advantages of machine-learning approaches are that they do not require any assumptions about the
underlying distribution of the data. They are robust to outliers, multicollinearity issues, and high-level
interaction terms.67 In fact, several interpretable ML (IML) techniques can even allow us to identify the
interactions between several variables at once and examine their joint marginal effect on the dependent
variable.68–70
We used two supervised ML techniques, namely random forest (RF) and eXtreme Gradient Boosting
(XGBoost), to to identify the leading predictors of CV-GID, ADRD, and inappropriate NSAID use. RF and
XGBoost are two of the most popular ensemble learning methods that combine several machine learning
techniques to decrease variance, bias, and improve predictions.71 Both algorithms use decision trees and build
multiple trees, however, gradient boosting builds one tree at a time and incorporates information about errors
made by all previously built trees to build new trees.72 XGBoost has been shown to achieve excellent prediction
8

accuracies in many classification tasks and is known for faster processing speeds and regularization to prevent
overfitting.73–75 Moreover, XGBoost allows tuning of several hyperparameters, , configurations external to the
model and whose value cannot be estimated from the data, to achieve better performance and avoid overfitting.
Additionally, we used 3-fold cross-validation with XGBoost to reduce overfitting and possible bias. RF, on the
other hand, is an ensemble learning method based on classification and regression trees (CART).76 It is a
supervised learning method that creates multiple decision trees simultaneously into a “forest”. Each tree is
constructed from a bootstrapped sample of all observations in the training dataset. A random subset of
independent variables is then selected at each node of each tree and the split is made such that the prediction
accuracy is maximized. The prediction for an observation is then made based on the highest number of times it is
classified (majority voting from all trees) belonging to a particular class (e.g. inappropriate NSAID use vs
appropriate NSAID use).
To improve the interpretability of the results from XGBoost and RF, and to summarize the associations of
selected features to the target variables, we used several novel interpretable machine learning techniques (IML)
namely SHapley Additive exPlanations (SHAP), feature interactions, and partial dependence plots. .68–70 These
IML techniques allowed us to explore the type (linear vs non-linear) and strength of the relationships between
the predictors and the target variables. Some of these techniques also allowed us to identify the interactions
between several variables which would not be possible with the standard statistical techniques. We used the best
practices with our ML techniques including the separation of the original dataset into training and test subsets.
We used the train dataset to build and train our model and tested the performance using test dataset.
Significance and Innovation
The research presented here, build upon extensive literature review to identify knowledge gaps and design
studies to fill them, employed several new approaches to test our specific hypotheses related to the treatment and
care for older adults with OA. Specifically, we used novel machine learning techniques with real-world health
insurance claims data to answer questions that are clinically relevant. Our research also employed several of the
newer interpretable machine learning techniques to improve the understanding of the “black-box” machine
learning models. This research focused on some of the highly significant clinical conditions with high
prevalence and/or enormous disease burden. Our study of the prevalence and predictors of inappropriate NSAID
9

use is the first to explore this topic in the US population. Additionally, our explorations of the predictors of CVGID and ADRD have not been carried out previously in older adults with OA in the US. We also used
interpretable machine learning methods to identify the interactions of NSAID use with other predictors and to
study the effect of such interactions on the risk of ADRD. Such an approach has not been previously used to
study the relationship between NSAID use and ADRD risk. With this approach, our research allowed us to
identify several subgroups of older adults with OA who can benefit from NSAID use as well as those in whom
there is no benefit related to ADRD risk reduction.
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Chapter 2
2 Predictors of Cardiovascular and Gastrointestinal Disorders among Older Adults with Osteoarthritis
Abstract
Objective: To identify the leading predictors of cardiovascular or gastrointestinal disorders (CV-GID) in a realworld cohort of older adults with osteoarthritis (OA).
Design: Data from Optum’s deidentified Clinformatics Data Mart were used to identify a retrospective cohort of
older adults with OA during 2015. These individuals were followed for two years to identify the occurrence of
CV-GID. Demographics and clinical information on the leading risk factors and confounding factors from health
insurance claims were obtained. Random forest with partial dependence plots (PDP) were used to identify the
leading predictors of CV-GID and to examine their associations with the risk of CV-GID. Multivariable logistic
regression was also used to examine the association of the leading predictors with the target variable.
Results: Our study cohort consisted of 45,385 older adults with OA (mean age 76.0 years and 66.3% female).
CV-GID were present in one in two older adults. Fragmentation of care index, chronic obstructive pulmonary
disease, polypharmacy, hypertension, and UTI were found to be the leading predictors of CV-GID in our study.
PDPs confirmed the positive relationship of all these predictors to the risk of CV-GID. After controlling for
other confounders, results from the logistic regression also found the top 5 leading predictors to be associated
with higher odds of CV-GID.
Conclusions: CV-GID are common among older adults with OA. Individuals with certain risk factors can be
monitored closely to reduce their risk of CV-GID. Machine learning methods with PDPs can be used to improve
their interpretability and inform decision-making.

11

Introduction
Osteoarthritis (OA) is a chronic age-related joint disease characterized by joint pain that disproportionately
affects older adults.77 Older adults with OA have higher rates of co-existing conditions and are at a higher risk
for other chronic conditions compared to those without OA.24 Of these conditions, cardiovascular disease (CVD)
and gastrointestinal (GI) disorders are of particular importance for several reasons. Evidence from recent studies
suggest that the risk and mortality of CVD are higher in individuals with OA.25–27 Both OA and CVD share a
few common risk factors including physical inactivity, age, and obesity among others.77,78 An increasing body of
evidence has shown that OA, although traditionally thought to be a noninflammatory condition, is associated
with chronic low-grade inflammation which may increase the risk of CVD.78–80 Emerging evidence also suggests
that inflammatory response may lead to GI complications such as gastroesophageal reflux disease (GERD).81
Furthermore, pain medications commonly used to treat adults with OA can also lead to an increased risk of CVD
and upper GI adverse events (AEs). The CV and GI AEs of non-steroidal anti-inflammatory drugs (NSAIDs)
are well documented.28,82 For example, according to a study by Ramakrishnan et al83, approximately 5-20% of
patients with long-term NSAID use develop peptic ulcer disease. There is also some evidence on the CV risk of
opioid analgesics.29,30,84
Published studies that are not specific to OA have provided evidence on the association of many factors to CVD
or GI disorders (CV-GID) using statistical85–87, or machine learning methods (Rajesh go2018; Anna Karen 2020;
Neil 2017).88–90 These factors include biomarkers (e.g. high cholesterol) clinical (e.g. hypertension, diabetes,
concomitant medications) and behavioral factors (e.g. smoking, physical inactivity). However, to date, there are
no published studies on a comprehensive list of factors associated with CV-GID. Examination of CV or GI
disorders is important because of a documented link between these two disorders.91–93 Several risk factors for
CVD have also been found to be associated with an increased risk for GI disorders.94 Additionally, the use of
low-dose aspirin for a primary or secondary prevention of CVD may also increase an individual’s risk for GI
complications.95,96 Specifically, the identification of the leading predictors of CV-GID among older adults with
OA holds significance because the prevalence of OA rises from under 15% in those younger than 60 years of age
to 33% among individuals in the age-group 60-70 years, and up to 43.7% in those with 80 years or older.6 Older
age itself is a leading risk factor for both CV and GI disorders.56,57,97 The increased use of pain medications
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among older adults with OA can increase their risk for potential CV-GID. Moreover, older adults with OA have
higher rates of multimorbidity98, including mental health conditions99 (Stubbs 2016) and polypharmacy.100 These
factors have been found to be associated with a higher risk for CV-GID perhaps due to drug-drug, drug-disease,
and disease-disease interactions.98,101,102 The identification and knowledge of leading predictors of CV-GID can
help clinicians and healthcare providers to identify certain groups of patients for heightened surveillance, closer
monitoring, and tailored treatment plans.
Therefore, the objective of the current study was to identify the leading predictors of CV-GID in older adults
with OA using machine learning approaches. We also used an interpretable machine learning technique to gain
insights into the associations of the leading predictors to CV-GID.
Methods
Study design
We employed a retrospective cross-sectional study design using data from two years. The study sample
consisted of older adults (age > 65 years) identified with OA during 2015 and followed for two years until the
end of 2016.
Data Source
The study cohort was selected from a 10% random sample of all individuals in the Optum De-identified
Clinformatics® Data Mart (Optum).61 The data consist of commercial and Medicare Advantage claims from
enrollees. The data are geographically representative of the commercially insured United States (US) population
and contain comprehensive information on demographics, prescription medications, diagnoses, and medical
services used by insured individuals. As data are deidentified, informed consent from patients was not required.
Clinical characteristics and medications were identified from claims using the International Classification of
Diseases-9th and 10th Revisions (ICD-9/10) codes, American Hospital Formulary Services (AHFS) codes,
Healthcare Common Procedure Coding System (HCPCS) codes, and National Drug Codes (NDC).
Study Cohort
One inpatient or two outpatient claims with (30 days apart) ICD-9 (715.xx) or ICD-10 diagnosis codes (M15.x,
M16.x, M17.x, M18.x, M19.x) were used to identify older adults (age > 65 years) with OA in 2015.103 Only
those enrollees with continuous enrollment in Medicare Advantage plans with both medical and pharmacy
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benefits during 2015 and 2016 were included in the study. Our study cohort comprised 45,385 older adults (age
> 65 years) with OA who met the study inclusion criteria.
Measures
Target Variable: Cardiovascular or Gastrointestinal Disorders (CV-GID):
CVD included in our study consisted of angina, myocardial infarction, other ischemic heart diseases, stroke, and
congestive heart failure. The GI disorders included dyspepsia, gastroesophageal reflux disorder (GERD, and
uncomplicated and complicated peptic ulcer disease (PUD). The target variable was a binary variable indicating
the presence or absence of at least one of the above-mentioned conditions. The ICD-9 and ICD-10 diagnosis
codes used to identify these conditions from the inpatient or outpatient health insurance claims are presented in
Table A2.1 in appendix.
Features/Predictors:
Features included in our analyses were guided by the modified Determinants of Health Outcomes and Chronic
Disease Model59 and were derived using published literature. Based on the model, the features included age and
sex (biological factors); the type of health insurance coverage (health maintenance organization (HMO) vs other
(access to care); duration and type (selective or non-selective) of NSAIDs, duration of prescription opioid, intraarticular corticosteroid use, and use of other medications (long-term (>60 days) use of oral corticosteroids, or
SSRIs) known to be risk factors for GI disorders, and polypharmacy (concomitant use of >6 different classes of
medications) (pharmacological treatment factors); physical therapy (non-pharmacological treatment factor); cooccurring chronic conditions including known CVD (e.g. hypertension, hyperlipidemia, obesity, and diabetes)
and GI risk factors (Helicobacter pylori infection) (health status factor); obesity and tobacco use (lifestyle); and
fragmentation of care index (FCI), and region (community resources). The FCI was calculated based on a
modified version of a previously validated continuity of care index.104 The value of the FCI takes into account
the following three factors: the total number of healthcare encounters, the number of different providers, and the
proportion of encounters to each of the providers. The FCI ranges from 0 (all encounters with the same provider)
to 1 (each encounter with a different provider) and higher values indicate fragmented care or care
discontinuation.
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For all medications, except intra-articular corticosteroids, NDC codes corresponding to only oral formulations
were used to identify medication use. Chronic conditions (dementia, cancer, asthma, chronic obstructive
pulmonary disease (COPD), hyperlipidemia, Helicobacter pylori (H.pylori) infection, diabetes, hypertension,
sleep disorders, arthritis and joint pain conditions other than osteoarthritis, headache or migraine, back or neck
pain conditions, and neuropathic pain, and pain related to OA, depression, anxiety, substance abuse disorders,
obesity, and urinary tract infection (UTI)) were identified using ICD9/ICD10 codes. HCPCS codes were used to
identify intra-articular corticosteroid use.
Analysis
We evaluated the univariate relationship between independent variables and the dependent variable using twotailed chi-square tests and independent t-tests, depending on the type of independent variable. We used both
standard statistical (multivariable logistic regression) and machine learning algorithms based on decision trees
(random forest) to identify the leading predictors of CV-GID. We chose the machine learning approach for their
ability to accommodate interactive effects (Friedman 2008).70 On the other hand, estimating interactive effects in
multivariable logistic regression framework with many predictors is challenging and often inaccurate.105,106
The Random forest (RF) is an ensemble learning method based on classification and regression trees (CART).76
It is a supervised learning method that creates multiple decision trees simultaneously into a “forest”. Each tree is
constructed from a bootstrapped sample of all observations in a dataset. A random subset of independent
variables is selected at each node of each tree and the split is made such that the prediction accuracy is
maximized. The prediction for an observation is then made based on the highest number of times it is classified
(majority voting from all trees) belonging to the CV-GID class (Yes vs No).
We used the randomForest package of R software suite version 3.6.3 (R Development Core Team; Vienna,
Austria) to build and run RF models with 32 independent variables. We used the best practices while building
the machine learning models. For example, we randomly split our dataset into the train and test subsets
consisting of 80% and 20% of total observations, respectively. The RF model was built using train data and its
performance was evaluated using test data. We report the results from test data in this paper unless otherwise
specified. The combination of the number of trees (ntree) at 500 and the number of randomly sampled
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independent variables at each split at 2 (mtry) gave the best performance in terms of out-of-bag error.76,107 To
derive the leading predictors of CV-GID, we relied on the mean decrease in accuracy measure. Under this
method, the ranking of leading predictors is derived based on the permutation of variables and resulting change
in the accuracy of the model. The more important a variable is, the larger the decrease in mean accuracy of the
model upon permutation of that variable.
Machine learning approaches are often perceived as having limited applicability in health outcomes research
because they do not provide a measure that summarizes both the direction and magnitude of the associations
between the leading predictors and the target variable, similar to those available in statistical learning methods
(example: adjusted odds ratios (AOR) in a multivariable logistic regression). To overcome this, in this study, we
used partial dependence plots (PDP)69, a “model-agnostic” technique that graphically summarizes such
relationships. PDPs display how the model predictions partially depend on a specific predictor and whether the
relationship is linear, non-linear, or complex. The dependence is based on the average marginal contribution of
each value of the predictor to the predicted probabilities of CV-GID. In our study, we derived one-way PDPs to
explain the direction of association, as well as, thresholds at which the associations may change. PDPs were built
using the pdp package in R.108
Traditional multivariable logistic regression was conducted to compare its predictive accuracy with the machine
learning algorithm, and to examine the association between the leading predictors and the target variable while
adjusting for other variables. There was no indication of multicollinearity between the independent variables
based on the variance inflation factor (VIF). In this article, we present adjusted odds ratios (AORs) and 95%
confidence intervals (CIs) for the leading predictors for comparison with the published literature. We used the
area under the receiver operating curve (AUROC) to measure the performance of RF and multivariable logistic
regression.
Results
Baseline characteristics of selected variables by CV-GID are presented in Table 1. CVD was identified in 25.6%
(n = 11,633), GI disorders in 39.6 % (n = 17,967), and CV-GID was identified in 51.4% (n = 23,340) of the
study cohort. Overall, a higher percentage of older adults with age 80 and over (57.4% vs 45.2% in 65-69 age
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group), had polypharmacy (59.3% vs 40.5%), COPD (68.7% vs 47.3%), hypertension (54.7% vs 34.9%), UTI
(63.1% vs 46.9%), anxiety (64.8% vs 47.9%), dementia (67.0% vs 49.7%), depression (63.8% vs 47.6%), and
H.pylori infection (53.8% vs 45.9%) had CV-GID compared to those without these characteristics (Table 1).
Individuals with CV-GID also had a higher FCI (0.46 vs 0.38), and longer duration of opioid use (108.0 vs 87.8
days) compared to those without CV-GID.
Predictive Performance:
Our tuned and the final random forest model consisted of 32 features, two of which were randomly
selected for splits, and 500 trees. We observed 66.2% accuracy, 71.7% sensitivity, 60.0% specificity, and 66.4%
positive predictive value (PPV) using test dataset. These metrics were comparable to 66.2% accuracy, 67.5%
sensitivity, 64.8% specificity, and 66.9% PPV obtained from the standard multivariable logistic regression.
AUROC values for RF and multivariable logistic regression models were 0.72 (95% CI, 0.71-0.73) and 0.73
(95% CI, 0.72-0.74), respectively.
Leading Predictors:
Variable importance plot for the top 10 predictors of CV-GID based on the mean decrease in accuracy from
random forest is presented in Figure 1. The most important predictor of CV-GID was the FCI followed by
COPD, polypharmacy, hypertension, UTI, anxiety, age, dementia, depression, and headache/migraine. The mean
accuracy plot suggests that without the FCI, COPD, or polypharmacy variables, the accuracy of the model will
be very low, suggesting that they are very important in predicting CV-GID in this cohort.
Association of the Leading Predictors to CV-GID:
The direction of association of the five leading predictors to CV-GID are summarized with univariate partial
dependence plots (PDPs) in Figure 2. These plots depict the direction of associations, as well as, the type of the
relationship (linear or non-linear) of the predictors with the target variable. For example, the most important
predictor, FCI, has a non-linear, but largely positive relationship with CV-GID. The FCI values up to 0.60 show
a linear and positive relationship with CVD or GI disorders with increasing values, suggesting a higher predicted
probability of CV-GID. However, values above this threshold show a negative relationship with the expected
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probability of CV-GID, suggesting that the association of FCI to CV-GID is complex and dependent on the
values of FCI. With respect to the other leading predictors, the PDP plots show that individuals with COPD,
polypharmacy, hypertension, or UTI had a higher expected probability of CV-GID compared to those who did
not have these conditions or characteristics. For example, it is clear from the PDP plot for polypharmacy that
having polypharmacy was associated with a higher expected probability of CV-GID. Moreover, the plot also
suggests that those without polypharmacy have a protective effect and had a lower risk of CV-GID risk. Similar
findings were observed for COPD, hypertension, and UTI variables.
For the ease of comparison with other published studies and to examine the association of the leading predictors
with CV-GID, we also present the adjusted odds ratios (AORs) and 95% confidence intervals from a
multivariable logistic regression in Figure 3. Although the regression model was adjusted for all 32 variables, the
results for the top 10 predictors are presented. The results show that all top 5 predictors of CV-GID were
associated with higher odds of having CV-GID after adjusting for age, sex, and other confounding variables.
Discussion
In this first study of its kind, we examined the leading predictors of and their associations with CV-GID risk in a
heterogeneous real-world population of older adults with OA. This is an important group of patients as they
often have multiple clinical and biological risk factors that place them at a higher risk for CVD or GI disorders.
While traditional risk factors for CVD and GI disorders are known, disease-disease, drug-disease, and drug-drug
interactions of OA and its treatment with combined CV-GID are not studied before. In our study cohort, one in
two older adults had CV-GID. Using a random forest technique, we predicted CV-GID with high sensitivity and
moderate specificity, which were comparable to the traditional multivariable logistic regression. These suggest
that without information on the severity of OA and clinical biomarkers of CV-GID, model accuracy estimates
can be modest.
We observed that the FCI was the leading predictor of CV-GID risk and the association of FCI to CV-GID risk
was complex with a threshold effect. For example, FCI levels up to 0.60 increased the risk of CV-GID. It is in
line with published studies, not specific to OA or CV-GID, that have reported negative outcomes with
fragmented care.109,110 It is plausible that our FCI measure is a proxy for resource utilization, and increased
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contact with the healthcare systems which may lead to more opportunities for the detection of CV-GID.
Additionally, older adults with multiple chronic conditions may be visiting multiple specialty providers making
it hard for a single provider to coordinate their care. Moreover, these chronic conditions may also independently
increase the risk for CVD or GI disorders.
The second leading predictor of CVD or GI disorders was COPD. This finding is not surprising given that
COPD affects older adults the most111 and has been shown to be associated with both GI conditions like
dyspepsia and GERD and CVD.101,112,113 This finding may suggest the need for closer examination of adults with
COPD for co-existing and new CVD and GI disorders. Polypharmacy was found to be another top predictor for
CVD or GI disorders. In our study, a simple measure of polypharmacy was also one of the leading predictors of
CV-GID which is consistent with the published literature reporting that the use of multiple medications increases
the risk for adverse drug reactions including heart failure and major bleeding.114,115 We also found that while
polypharmacy increased the risk of CV-GID, the absence of polypharmacy was associated with reduced risk.
This finding suggests that proven interventions that reduce the number of medications used by older adults with
OA may also help reduce the CV-GID risk.
Among other predictors, hypertension and UTI have been shown to increase the risk of CVD, but not GI
disorders.116–119 While there is enough awareness about hypertension and the risk of CVD, the link between UTI
and CVD needs to be further explored. The other two of the top 10 predictors, namely anxiety and depression,
are mental health conditions that were present in around one in five individuals in our study cohort and have
been shown to be associated with both CVD and GI disorders.99,102,120,121 Possible reasons for this association
may include the lack of integration between physical and mental health care which has been shown to increase
the risk of several chronic conditions.122 While some evidence points toward improved cardiac outcomes and
better quality of life with antidepressant use123,124, other studies have found no such association.125,126 Apart from
this disease-disease interaction, a drug-disease interaction between triptans, a first-line therapy for moderate to
severe migraines, and CVD is also well established. However, research suggests that triptan use is common in
adults with CV risk factors.127 Heightened vigilance for modifiable CVD and GI risk factors is recommended in
patients with these conditions. More studies in this area are warranted. Moreover, headache and migraine were
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also among the novel predictors of CV-GID in our study and have been shown to be associated with both CVD
and GI disorders.128,129
Our study has many strengths. It is the first study to identify the leading predictors of CV-GID in older adults
with OA using machine learning with a comprehensive list of factors available from medical claims. The use of
real-world data in the form of insurance claims allowed us to identify important variables relevant for clinical
decision-making. We also used interpretable machine learning methods to identify the relationship of the top
predictors with model predictions. However, the results from our study should be viewed in the light of its
following limitations. Being an observational retrospective cohort study, we cannot infer causality. We did not
have information on some variables including severity of OA, pain, lifestyle factors, and over-the-counter
medications which can affect various treatment and outcome related factors. As we used data from commercial
insurance claims from one large insurance provider, the results from our study cannot be generalized to all older
adults in the US. Additionally, results from PDPs may be inaccurate in the presence of variable interactions
which were not evaluated as part of this study.
Conclusion
CVD and GI disorders are common among older adults who have OA, with as many as 1 in 2 individuals
suffering from these conditions. Our findings suggest that these conditions can be predicted using certain
biological, health-, and treatment-related factors that are readily available in a clinical setting, such as
polypharmacy, comorbidities, and age. Our study demonstrates that machine learning methods can be used to
identify the leading predictors, as well as, to study the direction of their associations with the target variable.
Future research that includes OA severity and biomarkers are needed to improve the prediction accuracy, as well
as, confirm some of the novel predictors of CV-GID identified in our study.
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Figure and tables
Table 2.1 Selected Baseline Sample Characteristics;
Older Adults with Osteoarthritis (n = 45,385), 2015-2016
CVD or GI AEs
No CVD or GI AEs
Variable
N
%
N
%
All
23,340
51.4
22,045
49.8
Sex
Female
15725
52.3
14370
47.7
Male
7615
49.8
7675
50.2
Insurance Type
HMO
8223
49.8
8274
50.2
Other
15117
52.3
13771
47.7
Back or neck pain
Yes
13619
57.8
9935
42.2
No
9721
44.5
12110
55.5
Headache/migraine
Yes
3294
67.7
1570
32.3
No
20046
49.5
20475
50.5
Other arthritis or joint pain
Yes
14512
52.4
13204
47.6
No
8828
50.0
8841
50.0
Neuropathy
Yes
6511
61.7
4034
38.3
No
16829
48.3
18011
51.7
H.pylori infection
Yes
17073
53.8
14669
46.2
No
6267
45.9
7376
54.1
Anxiety
Yes
6088
64.8
3303
35.2
No
17252
47.9
18742
52.1
Substance abuse disorder
Yes
3001
61.4
1883
38.6
No
20339
50.2
20162
49.8
Depression
Yes
6782
63.8
3844
36.2
No
16558
47.6
18201
52.4
COPD
Yes
6058
68.7
2766
31.3
No
17282
47.3
19279
52.7
Hypertension
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p-value
<0.001

<0.001

<0.001

<0.001

<0.001

<0.001

<0.001

<0.001

0.018

<0.001

<0.001

<0.001

Table 2.1 Selected Baseline Sample Characteristics;
Older Adults with Osteoarthritis (n = 45,385), 2015-2016
CVD or GI AEs
No CVD or GI AEs
Variable
N
%
N
%
Yes
20736
54.7
17183
45.3
No
2604
34.9
4862
65.1
Urinary tract infection
Yes
8028
63.1
4698
36.9
No
15312
46.9
17347
53.1
Dementia
Yes
3052
67.0
1501
33.0
No
20288
49.7
20544
50.3
Obesity
Yes
6780
57.6
4990
42.4
No
16560
49.3
17055
50.7
SSRI use of 60 days or longer
Yes
3676
61.5
2298
38.5
No
19664
49.9
19747
50.1
Polypharmacya
Yes
No

p-value

<0.001

<0.001

<0.001

<0.001

<0.001

15656
59.3
10738
7684
40.5
11307
Mean and Standard Deviation of Continuous Variables
Mean
SD
Mean
Age
76.6
7.1
75.3
Fragmentation of Care Index (FCI)
0.46
0.22
0.38
Duration of non-selective NSAID use
(days)
28.8
79.1
29.4
Duration of selective NSAID use (days)
6.3
40.3
5.2
Number of IA corticosteroid injections
0.9
1.6
0.7
Number of physical therapy visits per
month
4.9
13.0
3.8
Duration of prescription opioid
108.0
123.6
87.8

40.7
59.5
SD
6.9
0.25

<0.001
<0.001

79.4
36.5
1.3

0.432
0.002
<0.001

10.6
114.7

0.004
<0.001

Note: The sample includes patients from De-identified Optum Clinformatics Data Mart.
a
Polypharmacy was defined as the concurrent use of 6 or more different classes medications
*Excludes opioid and NSAID combinations
COPD- chronic obstructive pulmonary disease; CVD- cardiovascular disease; GI- gastrointestinal; HMO, health
maintenance organization; IA- intra-articular; NSAID- non-steroidal anti-inflammatory drugs; OA- osteoarthritis; SDstandard deviation; SSRI- selective serotonin reuptake inhibitors
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Figure 2.1 Variable Importance Plot from Random Forest
Note: The sample includes 45,385 older adults with osteoarthritis from De-identified Optum Clinformatics Data Mart
(2015-2016)
COPD- chronic obstructive pulmonary disease; FCI- fragmentation of care index; UTI- urinary tract infection
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Figure 2.2 Univariate Partial Dependence Plots for Top 5 Predictors from Random Forest
Note: The sample includes 45,385 older adults with osteoarthritis from De-identified Optum Clinformatics Data Mart
(2015-2016)
COPD- chronic obstructive pulmonary disease; FCI- fragmentation of care index; UTI- urinary tract infection
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Figure 2.3 AOR and 95% CI for Top 5 Predictors of CV-GID
Note: The sample includes 45,385 older adults with osteoarthritis from De-identified Optum Clinformatics Data Mart
(2015-2016)
Regression model was adjusted for all 32 variables
AOR- adjusted odds ratio; CI- confidence interval; COPD- chronic obstructive pulmonary disease; CV-GID- cardiovascular
disease or gastrointestinal disorders; cardiovascular disease; UTI- urinary tract infection
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Chapter 3
3 A Machine Learning Approach to Identify Predictors of Inappropriate Non-Steroidal AntiInflammatory Drugs (NSAID) Use in Older Adults with Osteoarthritis
Abstract
Objective: To examine the prevalence of inappropriate non-steroidal anti-inflammatory drugs (NSAID) use and
identify its leading predictors in older adults with osteoarthritis (OA).
Design: A retrospective cohort of older adults (age > 65) with OA using data from Optum’s De-identified
Clinformatics® Data Mart was used. Calendar years 2015 and 2016 were used as baseline and follow-up
periods, respectively. Information on demographic and clinical characteristics was obtained at baseline.
Inappropriate NSAID use during the follow-up period was defined using the type (selective vs. non-selective),
duration of NSAID use and cardiovascular (CV) and gastrointestinal (GI) risk factors present during baseline.
eXtreme Gradient Boosting (XGBoost) with SHapley Additive eXplanations and cross-validated logistic
regression were used to identify the leading predictors of inappropriate NSAID use.
Results: Our study cohort consisted of 44,990 older adults with OA with a mean age of 75.9 years. Overall,
12.8% of the study cohort had inappropriate NSAID use, but the rate was disproportionately higher (44.5%) in
older adults with low CV and high GI risk. The XGBoost classifier identified non-selective and selective NSAID
use durations during the baseline period to be the top 2 predictors of inappropriate NSAID use at follow-up. Low
CV/high GI and high CV/low GI risk categories were also among the 15 leading predictors of inappropriate
NSAID use.
Conclusions: Older adults with OA and GI or CV risk factors for NSAID-related AEs were more likely to have
inappropriate NSAID use. Heightened surveillance of patients with continued NSAID use is warranted.
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Introduction
Each year, nearly 29 million adults in the United States (US) use non-steroidal anti-inflammatory drugs
(NSAID).38 NSAID are moderately effective in treating pain and are recommended by numerous clinical
guidelines for pain management.36,130,131 However, their use is associated with several cardiovascular (CV) and
gastrointestinal (GI) adverse events (AE), some of which can be life-threatening.28,132,133 It is estimated that each
year more than 100,000 adults are hospitalized and over 16,000 die from NSAID-related AEs in the US.42,134
Based on their affinity to inhibit cyclooxygenase-2 enzyme (COX-2), NSAID can be classified into nonselective and selective, which differ in their CV and GI safety profiles.28 While there is lower risk of GI AEs
with selective NSAID, both non-selective and selective NSAID have similar risk of CV AEs, except for
naproxen and ibuprofen.28,37 Research suggests that patients can experience NSAID-related AEs as early as 4
weeks after initiation.135–137 Therefore, clinical guidelines recommend that NSAID should be used at the lowest
possible dose for the shortest duration. Furthermore, their use should be in accordance with a person’s CV or GI
risk profile.36,138,139 Any use of NSAID not in line with a person’s GI or CV risk profile may be considered
inappropriate and may further exacerbate the risk of NSAID-related AEs.
Examination of inappropriate NSAID use among older individuals with osteoarthritis (OA) is particularly
important for several reasons. OA is a progressive degenerative disease affecting as many as 30 million adults in
the US and is most common in older adults.6 Acute and chronic pain are highly prevalent in OA patients; one in
four adults with OA report pain32 and 40% report moderate to severe pain interference with daily activities.19 In
real-world practice, 30% to 50% of older adults with OA receive prescription NSAID for pain relief.38–40,45,140
Additionally, the risk of NSAID-related AEs may be higher in older adults due to age-related loss of
physiological organ reserve, higher comorbidity burden, and associated polypharmacy which can lead to high
healthcare use and mortality.141 For example, it has been estimated that NSAID use results in 41,000
hospitalizations and 3,300 deaths per year among older adults.58 Nearly one quarter (23.5%) of adverse drug
reaction-related hospitalizations in older adults have also been found to be associated with NSAID.142
Furthermore, among adults with OA nearly 50% were found to be at high risk for CV and GI
complications.143,144 Given strict controls on opioid prescriptions due to the opioid use disorders epidemic, older
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adults with OA may increasingly rely on prescription NSAID. This may lead to higher rates of NSAID use in
adults with CV and GI risk factors that may be considered inappropriate.
Research examining inappropriate NSAID use among older adults with OA in the US is still lacking. Studies
conducted in other countries suggest that approximately half of adults with OA are not treated with NSAID
appropriate with their GI and CV risk profiles.44,45 Such inappropriate use of NSAID can add to the already high
burden of OA and may outweigh any potential benefits. Identifying the prevalence of inappropriate NSAID use
and its predictors are required to inform policy, clinical practice, and to develop tailored interventions targeting
older adults with OA who are already at high risk for CV and GI AEs.
Therefore, the primary objective of the current study was to examine the prevalence and leading predictors of
inappropriate NSAID use among older adults with OA using real-world data from a nationally representative
commercial health insurance claims and incorporating machine-learning approaches. We also examined the
association of CV and GI risk profiles at baseline to inappropriate NSAID use during the follow-up period.
Methods
Study design
A retrospective cohort study design with 2015 calendar year as baseline and 2016 as follow-up was used. The
cohort consisted of older adults (age > 65 years) with any type of OA at baseline. CV and GI risk profiles,
demographic characteristics, concurrent use of other potential OA treatments including intra-articular
corticosteroid or hyaluronic acid injections, opioids, and physical therapy were identified during the baseline
period. Data from the follow-up year were used to identify type (selective or non-selective), duration, and
appropriateness of NSAID use.
Data Source
The study cohort was selected from a 10% random deidentified sample of all individuals in the Optum Deidentified Clinformatics® Data Mart (Optum).61 The deidentified Optum data contain insurance claims records of
beneficiaries from a large commercial health insurance provider in the US along with patients with Medicare
Advantage plans contains commercial and Medicare Advantage claims. The data are geographically
representative of the commercially insured US population. Comprehensive longitudinal data on demographics,
diagnoses, medications, and other medical services provided to insured individuals are available in this database.
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Insurance claims from a combination of inpatient, outpatient, and pharmacy claims from years 2015 and 2016
were used for the present study. As data are deidentified, informed consent from patients was waived.
International Classification of Diseases, 10th Revision (ICD-10) codes, National Drug Codes (NDC), revenue
codes, and Healthcare Common Procedure Coding System (HCPCS) codes were used to identify relevant
clinical conditions, medications, and services and procedures.
Study Cohort
Older adults with OA were identified using one inpatient or two outpatient claims at least 30 days apart
consisting of OA diagnosis codes (ICD-10 codes M15-M19)103 during the baseline year. We required that these
adults be enrolled in Medicare Advantage plans with medical and pharmacy benefits during 2015 and 2016 (i.e.
24 months).
Measures
Target (i.e. Dependent) Variable: Inappropriate NSAID Use during follow-up (Yes/No)
Although clinical guidelines recommend “shortest” duration use for NSAID, there is no clear guidance on what
duration is considered appropriate especially among subgroups of patients like older adults who are at high risk
for NSAID-related adverse events. Therefore, we combined expert clinical opinion, available clinical evidence28,
practical guidelines43,138,139,145–148, and published literature44,53,144,149,150 to define appropriate duration of NSAID
use.
Appropriate duration of NSAID use considered two factors: 1) CV and GI risk, and 2) class of NSAID
medications. Individuals were classified as having inappropriate NSAID use if they received any type of NSAID
for 90 consecutive days with an allowed gap of 7 days between prescription refills irrespective of their CV or GI
risk. Individuals with GI or CV risk were considered to have inappropriate NSAID use if they met any one of the
following criteria: 1) high CV/high GI risk with any type of NSAID use for 60 consecutive days or longer; or 2)
high CV/low GI risk with selective or non-selective (except naproxen below 1000 mg/day or ibuprofen
below1200mg/day) NSAID use for 60 consecutive days; or 3) low CV/high GI risk with non-selective NSAID
use for 60 consecutive days or longer.
Features (i.e. Independent Variables):
CV and GI Risk Categories for Older Adults
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Older Adults with OA were classified into the following CV and GI risk categories: 1) high CV/high GI; 2) high
CV/low GI; 3) low CV/high GI; and 4) low CV/low GI (See Table 1 for definitions). This classification was
based on published guidelines or recommendations from the American College of Gastroenterology145,
American Heart Association43, American College of Rheumatology146, and the National Institute of Health Care
and Excellence37 and expert opinion from our study clinician. Clinical guidelines often define patients with high
GI risk as those having two or more minor GI risk factors. Please note that as older age itself is a minor risk
factor56,57,151 and our study sample included only older adults, the presence of at least one other minor risk factor
(all GI risk factors except complicated peptic ulcer disease in Table 1) placed a person in the high GI risk
category. We used ICD-10 codes to identify CV and GI conditions (see Table A3.1 appendix) and NDC codes to
identify concurrent medications from pharmacy claims during baseline.
All other features (including 31 features with 36 indicators) included in our analyses were guided by Andersen’s
Healthcare Utilization Model60 and previously published literature. These features included: 1) predisposing
factors: age and sex, 2) enabling: type of health insurance coverage; 3) need factors: chronic conditions
including asthma, cancer, cardiac arrhythmias, chronic obstructive pulmonary disease (COPD), dementia,
anxiety, depression, diabetes, hyperlipidemia, hypertension, substance abuse disorders, other pain conditions
(e.g. arthritis and joint pain conditions other than osteoarthritis, headache, migraine, back or neck pain
conditions, neuropathic pain), pain related to OA (i.e. pain in joints commonly affected by OA including knee
and hip), duration and type of NSAID use (selective vs non-selective), pain-related treatment (opioid, intraarticular hyaluronic acid and corticosteroids, physical therapy) 4) life-style practices (obesity and substance use),
and 5) external environment (region, the fragmentation of care index (FCI)152).
Analytic Approach
We chose two machine learning algorithms, namely cross-validated logistic regression (CVLR) and eXtreme
Gradient Boosting (XGBoost) to identify the leading predictors of inappropriate NSAID use as well as examine
the association of CV and GI risk factors to inappropriate NSAID use. We selected the machine learning
algorithms for their predictive accuracy and handling of outliers, multicollinearity, and high-level interaction
terms.67
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Random forest and XGBoost are two of the most popular ensemble learning methods that combine several
machine learning techniques to decrease variance, bias, and improve predictions.71 Both algorithms use decision
trees and build multiple trees, however, gradient boosting builds one tree at a time and incorporates information
about errors made by all previously built trees to build new trees.72 XGBoost has been shown to achieve
excellent prediction accuracies in many classification tasks and is known for faster processing speeds and
regularization to prevent overfitting.73–75,153–155
Data analyses involved the following steps: data pre-processing, model building, model validation, model
performance evaluation, deriving feature importance, and interpretation of results (i.e. a positive or negative
relationship of each variable with the target variable).
All data pre-processing tasks were performed using SAS 9.4 (SAS Institute Inc. 2010, Cary, NC, USA). In
preparation for the XGBoost, we used one-hot encoding, a process in which the values of categorical variables
were converted into binary indicators with values of zero and one.
We followed the best practices while building models with the machine learning algorithms. These included: a
random split of our dataset into training (70%) and testing (30%) subsets; using the test (unseen) subset data to
test the performance of the models; k-fold validation; and tuning of hyper-parameters. We tuned
hyperparameters, configurations external to the model and whose value cannot be estimated from the data, to
train the models using XGBoost to achieve better performance and avoid overfitting. We used the grid search
method of the caret package in R software suite version 3.6.3 (R Development Core Team; Vienna, Austria) for
this. The final set of hyperparameters used in our model included the number of trees (800), learning rate (eta =
0.01), minimal loss to expand on a leaf node (gamma=0), maximum tree depth (max_depth=4), subsample
proportion (subsample=0.75), proportion of variables to randomly pick from for each tree (colsample_bytree =
0.6), and the minimum sum of instance weight needed in a child node (min_child_weight=1).
We used 3-fold cross-validation to validate our models. Model fit was then evaluated using area under the
receiver operating curve (AUROC). We also compared models on other performance metrics such as accuracy,
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positive predictive value (i.e. precision), sensitivity (i.e. recall), specificity, F1-score (i.e. harmonic mean of
precision and recall) and kappa statistic.
To improve the interpretability of the results from XGBoost and to summarize the associations of selected
features to inappropriate NSAID use, we used a novel interpretable machine learning technique called SHapley
Additive exPlanations (SHAP).68 SHAP provides not only feature importance but also how much each feature
contributes to the model prediction (global interpretability). With SHAP, feature contribution is derived by
estimating the average marginal contribution of a specific feature to the model by using permutation and
combinations of all features. We present feature importance and feature contribution through visual
representation using a summary plot and a feature importance plot. Shapley values for XGBoost model were
obtained using SHAPforXGBoost package in R 3.6.3.
To facilitate the comparison of our results with published literature, we also present adjusted odds ratios (AOR)
and 95% confidence intervals (CI) from the CVLR. All data management and descriptive statistics were
completed with SAS 9.4 (SAS Institute Inc. 2010, Cary, NC, USA). Machine learning algorithms were run using
R version 3.6.3 (R Development Core Team; Vienna, Austria).
Results
Our study cohort consisted of 44,990 older adults with OA with mean age of 75.9 years, 66.4% were females,
and 55.3% had OA-related pain during the baseline period (Table 2). Overall, a majority (56.1%) of our study
cohort did not have CV or GI risk factors during the baseline period while 43.9% had either CV or GI risk.
Specifically, 7.5% of older adults had high CV/high GI risk; 9.4% had high CV/low GI risk; 27.0% low CV/high
GI risk. Nearly 1 in 8 older adults (12.8%) had inappropriate NSAID use during the follow-up period (Table 2).
Figure 1 displays the percentages with inappropriate NSAID use by CV and GI risk categories. The rates of
inappropriate NSAID use during the follow-up period were: 8.8% among older adults with high CV/high GI;
5.6% among those with high CV/low GI; 44.5% among those with low CV/high GI; and 41.0% among those
with low CV/low GI.
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Figure 2 presents the unadjusted odds ratios (UOR) and 95% CIs for inappropriate NSAID use by selected
baseline characteristics. Compared to older adults with low CV/low GI risk, those with low CV/high GI and high
CV/high GI were more likely to have inappropriate NSAID use and those with high CV/low GI were less likely
to have inappropriate NSAID use. With respect to other factors, higher age and enrollment in an HMO plan were
associated with lower odds of inappropriate NSAID use. On the other hand, female gender, coexisting other pain
conditions, OA-related pain, anxiety, substance abuse disorder, depression, and a higher number of opioid
prescriptions and intra-articular corticosteroid injections were associated with higher odds of inappropriate
NSAID use.
Model Performance Comparison
Both XGBoost and CVLR were trained on a set of 31 features. Performance metrics for models using test data
are presented in Table 3. Both models had area an under the receiver operating curve (AUROC) value of 0.92
(95% CI: 0.91-0.93) and 0.91 (95% CI: 0.90-0.92), respectively. While both models had similar accuracy and
specificity, CVLR had better precision (0.83 vs 0.81). On the other hand, XGBoost performed better on all other
metrics being compared including recall, F1 score, and kappa statistic.
Feature Importance and Model Interpretation
The top 15 predictors of inappropriate NSAID use from the final XGBoost model are presented in Figure 3. This
figure displays both feature importance and feature effects. Each dot in the figure represents a single observation
and low and high feature values are presented on a continuum with yellow representing low values and purple
representing high values. As all categorical variables were converted into binary indicators, zero (i.e., absence) is
indicated with yellow dots and one (i.e. presence) is represented by purple dots. The x-axis represents the
marginal contribution of a feature to the change in predicted probability of inappropriate NSAID use. In terms of
interpretation, for example, baseline non-selective NSAID use measured in days supplied, is the most important
predictor of inappropriate use, as indicated by the higher marginal contribution. For the categorical feature
HMO, ranked 8th in terms of feature importance, older adults enrolled in an HMO plan were less likely to have
inappropriate NSAID use as suggested by the negative marginal contribution. For CV and GI risk categories,
high CV/low GI and low CV/high GI ranked 10th and 14th in terms of importance and higher values for these
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variables (purple dots) were associated with a higher probability of inappropriate NSAID use. Other top
predictors of inappropriate NSAID use were: fragmentation of care index, the number of selective NSAID use
days, age, the number of opioid prescriptions and intra-articular corticosteroid injections, the number of physical
therapy visits, enrollment in an HMO plan, other pain conditions, hyperlipidemia, female gender and South
region (Figure 3).
The associations and average contributions of features to the absolute predicted probability of inappropriate
NSAID use are presented in Figure 4A. Red bars indicate positive association and green bars indicate negative
association of features with inappropriate NSAID use. For example, the number of non-selective NSAID use
days at baseline was the most important predictor and it increased the absolute values of the predicted
probability of inappropriate NSAID use at follow-up by an average of 0.139. Both the low CV/high GI and high
CV/low GI risk categories were associated with a small but positive increase in the predicted probability of
inappropriate NSAID use at follow-up. Although age and fragmented care index were associated with lower
predicted probabilities of inappropriate NSAID use, figure 3 highlights the presence of heterogeneity in
prediction for these two variables. A closer examination of the distribution of SHAP values with different values
of these variables (figure not shown) suggested that for similar fragmented care index or age values, the
probability of inappropriate NSAID use varied in both positive and negative directions.
Figure 4B presents results from CVLR on inappropriate NSAID use. Although the model was adjusted for all of
the features mentioned above, results are presented only for the top 15 predictors identified by the XGBoost
algorithm. The AORs indicate that longer duration of non-selective or selective NSAID use were associated with
higher odds of inappropriate NSAID use. Similarly, the low CV/high GI and high CV/low GI risk categories
were associated with higher odds of inappropriate NSAID use. While most of the feature associations with
inappropriate NSAID use were similar to those derived from XGBoost algorithm, some were different. For
example, female gender, hyperlipidemia, OA-related pain, and the South region were not found to be
significantly associated with inappropriate NSAID use in CVLR. This could be due to the presence of nonlinear
relationships of these variables to inappropriate NSAID use.
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Discussion
In our study cohort of older adults with OA, one in eight older adults had inappropriate NSAID use. Although
clinical guidelines recommend caution with long-term use of NSAID in older adults37,145,146,156, we observed that
44.5% of adults with low CV/high GI, 5.6% with high CV/low GI, and 8.8% with high CV/high GI risk had
inappropriate NSAID use. We also observed that long-term non-selective NSAID use was more common than
selective NSAID use (8.5% vs 1.9% with consecutive 90 days use) in these patients. Previous research has
shown that non-selective NSAID can increase the risk of both GI and CV AEs within 4 weeks of use.135–137
Results from XGBoost further suggested that high CV/low GI and low CV/high GI risk categories were two of
the top 15 predictors of inappropriate NSAID use in our study cohort.
Our study findings of highly prevalent long-term NSAID use among those with existing CV and GI risk is
concerning. This finding is in line with other published studies,44,45,53 which also reported that inappropriate
NSAID use is common in patients with OA. Although our study did not explore the reasons for NSAID
prescriptions, a plausible reason could be the lack of alternative effective pain medications. Reviews of
comparative effectiveness of pain medications suggest that there is no “perfect” pain medication and NSAID
may be the safer option available to both patients and physicians.157 With the opioid epidemic in the US and
resulting stricter controls on their use, physicians and patients may rely on NSAID for pain relief despite adverse
consequences. As NSAID will continue to hold an important place in the clinical management of pain for OA
patients, our findings suggest a need for heightened surveillance of older adults with OA and co-existing CV and
GI conditions. Clinicians may benefit from using tools like the GI risk score tool 158 to identify patients at high
risk for GI AEs and to individualize their treatment plan. Drug utilization review system and computerized
decision support tools may help to identify such patients and make changes to their treatment as necessary.
We also found that baseline NSAID use was the leading predictor of inappropriate NSAID use during follow-up.
This finding is consistent with another published study on high-risk primary care patients which reported that
prior NSAID use was strongly associated with current use.159 It is possible that physicians and patients may
compare the risks and benefits of types of pain medications and continue NSAID use because NSAID may be
perceived to have lower risk compared to other medications. For example, in one study that compared NSAID
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with opioids, it was found that opioids were associated with a greater risk (77% higher) of CV events. 160 This
finding combined with other reports56,161–163 of an increased risk of AEs with continued NSAID use in adults
with pre-existing risk factors call for individualized pain management approaches to mitigate risks and improve
safety.
We also observed that older adults with visits to multiple providers, i.e. higher fragmentation of care index, had
a lower probability of inappropriate NSAID use. While this finding may be counter-intuitive, it is plausible that
older adults with severe OA may not get sufficient symptomatic relief from NSAID and may visit more
specialists for alternative treatment options. It could also be due to the possibility of a provider different than the
original prescriber taking a note of patients’ inappropriate NSAID use and making changes to their treatment
plan. Examination of mean and spread of SHAP values for this variable suggested that while the average
contribution of this variable is negative, there is considerable variation in the probability of inappropriate
NSAID use. Further research into what factors related to care fragmentation lead to an increase in the probability
of inappropriate NSAID use is needed.
In our study, we observed that patients using other pain medications such as opioids and intra-articular
corticosteroids at baseline also had a higher probability of inappropriate NSAID use. The combined use of
multiple classes of pain medications is common among adults with OA or those with chronic pain and has been
increasing over time.164,165 Studies have shown that combined use of opioids and NSAID may provide effective
pain relief in 90% of adults with chronic pain166, despite increased risk of AEs associated with pain medications.
It is possible that older adults with OA are prescribed multiple pain medications with different mechanisms of
action to achieve a synergistic effect. Patients with moderate or severe pain have been shown to regularly use
combination analgesics which may explain the higher likelihood of such patients receiving inappropriate
NSAID.167
Higher number of physical therapy visits during the baseline period were associated with a lower probability of
inappropriate NSAID use, suggesting that non-pharmacological interventions may need to be considered in high
CV and GI risk patients to reduce the risk of NSAID-related AEs. Physicians may also consider a multimodal
approach that combines pharmacological and non-pharmacological treatments for pain relief in OA adults. An
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alternative explanation could be that older OA patients using physical therapy may be more physically active
and/or may have less severe OA requiring shorter or no treatment with NSAID.
In summary, the results from our study suggest a need for heightened surveillance of older adults with OA and
CV and GI conditions, who require NSAID. Older adults who have multiple risk factors (e.g. females with
baseline long-term NSAID use and high CV or GI risk) that increase the probability of inappropriate NSAID
use should be watched closely for their NSAID use, including the over-the-counter (OTC) drugs. The advent of
new therapies with the ability to target the underlying pathophysiology of OA may help reduce the reliance of
patients on NSAID against recommendations.168
The limitations of our study include its retrospective and observational nature; the possible underestimation of
clinical conditions in claims data; not capturing patients who do not routinely see clinicians or who do not use
health services; lack of information on variables that can affect NSAID use (e.g. patients’ dietary and personal
health habits, OTC NSAID use including low-dose aspirin, OA severity, pain, and patients’ response to pain
treatment) and whether or not the filled NSAID prescriptions were actually used by patients; and lack of
generalizability to all older adults in the US. Despite these limitations, our study has many strengths. It is the
first study to: document the rates of inappropriate NSAID use in a cohort of older adults with OA; examine the
prevalence of combinations of CV and GI risk factors; and employ machine learning algorithms with a
comprehensive list of 31 features to identify leading predictors and direction of associations of these features
with inappropriate NSAID use.
Conclusion
Our findings suggest that a majority of older adults with OA received prescriptions for NSAID despite their high
CV or GI risk profile. Our study also demonstrated that predictive models can be used to identify the predictors
of inappropriate NSAID use and some of the leading predictors were modifiable such as the type of NSAID,
fragmented care, use of other pain medications, and the presence of other pain conditions. Such information can
be used to influence policy, clinical practice, and patient safety. Future studies with a prospective cohort design
that explore the reasons for long-term NSAID use, despite high CV and GI risk profile are warranted to inform
targeted interventions in reducing NSAID-related AEs.
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Table 3.1. Identification of High Risk Older Adults44,53,56,57,144,149–151,169–171
Gastrointestinal risk factors (at least one of the
Cardiovascular risk factors (at least one of the
following)
following)
Complicated peptic ulcer disease
Angina
Uncomplicated peptic ulcer disease
Stroke
Dyspepsia
Myocardial infarction
Gastroesophageal reflux disorder
Congestive heart failure
Concomitant use of one of the following drugs
with NSAIDa:
Corticosteroids
Antiplatelets
Selective serotonin reuptake inhibitors
Aspirinb
Anticoagulants
NSAID- non-steroidal anti-inflammatory drugs
See appendix for ICD-10 codes used to identify these conditions
a
Concomitant use of at least 7 consecutive days was required
b
Over-the-counter aspirin use was not captured
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Table 3.2 Selected Baseline Sample Characteristics;
Older Adults (age > 65) with Osteoarthritis (n = 44,990);
Optum Clinformatics Data Mart 2015-2016
Variable
N/Mean Percentage/SD
All
44,990
100.0
Age
65-69
10,315
22.9
70-74
11,330
25.2
75-79
8,957
19.9
80+
14,388
32.0
Sex
Female
29,853
66.4
Male
15,137
33.6
Region
Northeast
6,034
13.4
Midwest
10,862
24.1
South
16,410
36.5
West
11,684
26.0
Insurance Type
HMO
16,314
36.3
Other
28,676
63.7
Other Pain Conditions
Yes
15,733
35.0
No
29,257
65.0
OA-related pain
Yes
24,880
55.3
No
20,110
44.7
Anxiety
Yes
6,285
14.0
No
38,705
86.0
Substance abuse disorder
Yes
3,354
7.5
No
41,636
92.5
Depression
Yes
7,620
16.9
No
37,370
83.1
Fragmentation of care index
0.44
0.28
Number of IA hyaluronic acid injections
0.2
0.9
Number of IA corticosteroid injections
0.8
1.5
Number of physical therapy visits
4.4
12.0
Number of opioid prescriptions
2.0
4.2
Any NSAID use
Yes
11,891
21.6
No
33,099
78.4
CV/GI Risk
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Table 3.2 Selected Baseline Sample Characteristics;
Older Adults (age > 65) with Osteoarthritis (n = 44,990);
Optum Clinformatics Data Mart 2015-2016
Variable
N/Mean Percentage/SD
All
44,990
100.0
High CV/high GI
3,383
7.5
High CV/low GI
4,233
9.4
Low CV/high GI
12,145
27.0
Low CV/low GI
25,229
56.1
Number of days of non-selective NSAID use
29.3
79.5
Number of days of selective NSAID use
5.8
38.7
Inappropriate NSAID use
Yes
5,772
12.8
No
39,218
87.2
Note: Based on 44,990 older adults (age > 65) with OA using data from Optum De-identified Clinformatics® Data Mart
who were continuously enrolled in Medicare Advantage plan during 2015-2016.
CV- cardiovascular; GI- gastrointestinal; HMO, health maintenance organization; IA, intra-articular; NSAID- non-steroidal
anti-inflammatory drugs; OA- osteoarthritis
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Table 3.3. Model Performance Metrics Using Test data*;
Inappropriate NSAID Use in Older Adults with Osteoarthritis;
Optum Clinformatics Data Mart 2015-2016
XGBoost
Cross-validated Logistic Regression
Accuracy
0.93
0.93
Precision
0.81
0.83
Recall
0.63
0.58
F1 Score
0.71
0.68
Specificity
0.98
0.98
Kappa
0.67
0.64
AUROC
0.92
0.91
Note: Based on 44,990 older adults (age > 65) with OA using data from Optum De-identified Clinformatics® Data Mart
who were continuously enrolled in Medicare Advantage plan during 2015-2016.
*Test data consisted of a 30% random sample of the original dataset

Figure 3.1 Percentage of Older Adults with Osteoarthritis and Inappropriate NSAID Use by Risk
Categories
Note: Based on 44,990 older adults (age > 65) with OA using data from Optum De-identified Clinformatics® Data Mart
who were continuously enrolled in Medicare Advantage plan during 2015-2016.
CV- cardiovascular; GI- gastrointestinal; NSAID- non-steroidal anti-inflammatory drugs; OA- osteoarthritis
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Figure 3.2 Unadjusted Odds Ratios and 95% CI for Inappropriate NSAID Use in Older Adults with
Osteoarthritis
Note: Based on 44,990 older adults (age > 65) with OA using data from Optum De-identified Clinformatics® Data Mart
who were continuously enrolled in Medicare Advantage plan during 2015-2016.
Unadjusted associations significant at p < 0.05
CV- cardiovascular; GI- gastrointestinal; HMO, health maintenance organization; IA, intra-articular; NSAID- non-steroidal
anti-inflammatory drugs; OA- osteoarthritis
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No. of non-selective NSAID days
No. of non-selective NSAID days
Fragmentation of care index
Age
No. of opioid prescriptions
No. of physical therapy visits
No. of IA corticosteroid injections
Low CV/high GI risk
Insurance type: HMO
OA-related pain
High CV/Low GI
Region: South
Female
Other pain conditions
Hypertension

Figure 3.3 Variable Importance and SHAP Summary Plot
Note: Based on 44,990 older adults (age > 65) with OA using data from Optum De-identified Clinformatics® Data Mart
who were continuously enrolled in Medicare Advantage plan during 2015-2016.
The x-axis represents the marginal contribution of a feature to the change in predicted probability of NSAID use
Feature value refers to the actual value of the predictors (e.g. values for no. of non-selective NSAID days will range from 0
to 365 with values closer to 0 represented with yellow and values closer to 365 represented with purple dots)
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Figure 3.4 Association of Top Predictors to Inappropriate NSAID
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Note: Based on 44,990 older adults (age > 65) with OA using data from Optum De-identified Clinformatics® Data
Mart who were continuously enrolled in Medicare Advantage plan during 2015-2016.
Red bars/dots indicate an increase in the predicted probability/higher odds of inappropriate NSAID use, respectively
Green bars/dots indicate a decrease in the predicted probability/lower odds of inappropriate NSAID use, respectively
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Chapter 4
4 Nonsteroidal Anti-inflammatory Drugs and Alzheimer’s Disease and Related Dementia (ADRD)
in Older Adults with Osteoarthritis (OA): Prediction with Random Forest
Abstract
Objective: To examine whether duration of NSAID use is a leading predictor of ADRD in older adults
with OA using machine learning approaches and to assess the modifying influence of other variables on
this relationship.
Methods:
In this retrospective cohort study, older adults with OA during the 2014 baseline period were identified
using Optum’s De-identified Clinformatics Data Mart®. Incident ADRD was ascertained in the 2015-16
follow-up period using ICD codes. We used random forest to identify the leading predictors of ADRD.
We used univariate and bivariate partial dependence plots to study the association of the leading
predictors to ADRD and to study the interactions between NSAID duration and other variables on ADRD
risk.
Results:
Our study cohort comprised 16,496 older adults with OA, of whom 6.4% were diagnosed with ADRD.
Random forest analysis indicated age, NSAID duration, delirium, polypharmacy, and OA-related pain to
be the top 5 leading predictors of ADRD (AUC = 0.72). The effects of NSAID duration on ADRD risk
varied based on the interacting variable. While longer duration of NSAID use was associated with a
higher risk of ADRD in females, and in individuals with OA-related pain, sleep disorders,
hyperlipidemia, hypertension, or atherosclerosis, it was associated with a lower risk of ADRD in
individuals with stroke, delirium, depression, or anxiety disorders.
Conclusion:
The risk of incident ADRD in older adults with OA can be predicted using biological and clinical
characteristics. The relationship between NSAID use and ADRD risk is complex and depends on multiple
factors.
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Introduction
There is increasing evidence for an effect of Osteoarthritis (OA) on ADRD1,2, a progressive
neurodegenerative disorder associated with cognitive impairment, disability, and higher mortality in older
adults. Both OA and ADRD are age-related conditions that share similar risk factors and inflammatory
mechanisms.3–6 Evidence from a recent meta-analysis of six observational studies and four longitudinal
studies suggest that OA is associated with a higher ADRD risk.2 Independently, OA and ADRD have
significant negative health consequences that can impact quality of life and activities of daily living. 7,8
The prevalence of both OA and ADRD increase with age.9,10 Approximately, one in 3 older adults (>65
years) suffers from OA10, whereas one in 10 people age 65 and older has ADRD.9 Recent estimates also
suggest that the prevalence of ADRD as well as OA are expected to increase by 200% by 2050 and by
60% by 2040, respectively.9,11
Among the multiple risk factors that have been linked to ADRD, modifiable conditions such as
diabetes, depression, cardiovascular disease (CVD), and lifestyle factors are of particular importance,
given the current lack of effective treatments for ADRD.12,13 Chronic pain, a modifiable factor and a
hallmark symptom in individuals with OA, may also play a significant role in the development of
ADRD.1,14,15 It has been reported that older adults with OA and pain may be particularly at a higher risk
for incident ADRD.1,16 While the underlying causes of ADRD remain poorly understood, some evidence
points toward the possible role of pain-related neuro-inflammation on brain damage and related oxidative
stress.17,18 Specifically, the expression of cyclooxygenase-2 (COX-2), an enzyme inhibited by
nonsteroidal anti-inflammatory drugs (NSAIDs), has been shown to be higher in brain cells of patients
with ADRD.19,20
Given the link between inflammation and ADRD, the higher prevalence of chronic pain in
individuals with OA, and the greater use of NSAIDs by older adults with OA, it is plausible that NSAIDs
may lower the risk of ADRD in adults with pain conditions such as OA.11,21,22 Results from several
studies examining the association between NSAIDs and ADRD in populations not specific to OA have
found a lower risk for ADRD associated with NSAID use.23–26 Yet some other studies did not find such an
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association.27–29 It is important to note that many of these studies focused on average treatment effects and
did not analyze interactive effects of NSAID on the risk of ADRD. As heterogeneous treatment effects
are often the norm rather than the exception30, it is likely that NSAIDs may reduce the risk of ADRD in a
subgroup of individuals with OA. Thus, an investigation of incident ADRD in older adults with OA
requires special attention to not only the average treatment effects but also the interactive effects.
Despite the growing evidence for a link between OA and ADRD2, the leading predictors of
ADRD in older adults with OA are not known. Moreover, the relationship between NSAID use and
ADRD risk in this group of patients remains mostly unexplored. It is particularly important to explore
such relationship in older OA patients as at least half of the adults with OA use NSAIDs21 for pain relief.
Additional knowledge of the role of NSAIDs in ADRD may help researchers explore further avenues of
reducing the risk of ADRD in this at-risk patient population. Moreover, identifying specific subgroups of
patients that may receive benefit or harm from such interventions could help the development of future
interventions.
Therefore, the objective of the current study was to identify whether NSAIDs use one of the
leading predictors of incident ADRD in older adults with OA using real-world data from the health
insurance claims of a geographically diverse group of individuals. Additionally, we also examined the
interactive effects of NSAIDs using interpretable machine learning techniques to identify the subgroups
of patients for whom NSAID use could be beneficial or harmful with respect to ADRD risk.
Methods
Study Design
We used a retrospective cohort study design with calendar year approach spanning over three
from 2014 to 2016. Calendar year 2014 was taken as the baseline period and calendar years 2015 and
2016 were used for follow-up. All independent variables were measured during the baseline year and
incident ADRD was measured during the follow-up period.
Study Cohort: ADRD-free Older Adults with OA
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Our study cohort included: Older adults (age > 65 years) with an OA diagnosis (ICD-9 code
715.xx; ICD-10 codes M15.x- M19.x)31 in either one inpatient or two outpatient claims and without a
diagnosis of ADRD32 during the baseline period were identified. These individuals were required to be
continuously enrolled in Medicare advantage plans and have both health and pharmacy benefits
throughout the observation period. Individuals who died during the follow-up were excluded from the
study. Our final analytic study cohort comprised 16,496 older individuals with OA.
Data Source
We used real-world health insurance claims data obtained from a 10% random sample of all
enrollees in the Optum De-identified Clinformatics Data Mart (Optum).33 Optum data consist of
adjudicated health insurance claims from geographically diverse enrollees of both commercial and
Medicare Advantage plans. These data contain information on various aspects of clinical encounters for
enrolled individuals including demographics, diagnoses, prescribed medications, and medical procedures
and services. Such information is coded using standard coding systems including but not limited to the
International Classification of Diseases-9th and 10th Revisions (ICD-9/10) codes, National Drug Codes
(NDC), American Hospital Formulary Services (AHFS) codes, and Healthcare Common Procedure
Coding System (HCPCS) codes. Use of these standard terminologies allows researchers to identify of
various clinical conditions, their treatments, and other healthcare resource use.
Measures
Target variable: ADRD
Health insurance claims for inpatient or outpatient services were evaluated for the diagnosis
codes for ADRD using a validated algorithm published by the Centers for Medicare and Medicaid
Services (CMS).32 The CMS algorithm uses ICD-9 or ICD-10 codes from medical claims to identify
ADRD patients.32 All types of dementia including Alzheimer’s dementia, vascular dementia, and others
were included in our definition of ADRD.
Predictors:
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The predictors included in our study were measured during the baseline period; predictors were
selected based on published literature and included factors known or suspected to affect risk of ADRD.34
These included age, sex, health conditions (diabetes, hyperlipidemia, hypertension, ischemic heart
disease, chronic obstructive pulmonary diseases (COPD), depression, anxiety disorders, atrial fibrillation,
congestive heart failure, stroke, delirium, sleep disorders, other chronic pain conditions), lifestyle factors
(obesity and substance use disorder), OA-related pain (i.e. pain in knee or hip joints), duration of NSAID
use, polypharmacy (concurrent use of > 6 distinct classes of medications other than NSAIDs), and other
medications (antihypertensives, lipid-lowering drugs, and opioids). The medical conditions were
identified from claims data using ICD-9/ICD-10 codes. The duration of NSAID use (in days) during
baseline was captured by summing the days’ supply for each filled NSAID prescription. The oral
formulations of both non-selective and selective NSAIDs were included in our study as part of the
NSAID use definition. All categorical predictors were binary coded for the machine learning models,
whereas age and duration of NSAID use were treated as continuous variables.
Analytic Approach
We used two-tailed chi-square tests with 5% significance to examine the univariate association of all the
predictors with ADRD. We used random forest (RF), an ensemble machine learning technique based on
decision trees, to identify the leading predictors of ADRD in our study cohort. The RF is a well-known
machine learning technique based on classification and regression trees (CART).35,36 The RF model uses a
decision tree approach with bootstrapped samples with replacement to derive a training dataset equal in
size to the original training dataset to build each tree. Approximately, 1/3rd of the training dataset (out-ofbag (OOB) sample) is left behind in bootstrapping, which is then used to validate the accuracy of the
model using OOB error. The RF also uses random selection of variables and numerous trees (forest) to
build a predictive model. These hyperparameters (number of trees and random selection of variables) can
be used to fine-tune the model to achieve high predictive performance.
The random forest model was trained using 80% of the original data. The performance of the
trained model is then tested using the rest 20% of the data which has not been previously exposed to the
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model. We used the randomForest37 package of R software suite version 3.6.3 (R Development Core
Team; Vienna, Austria) to build and run the RF model with 23 predictors, 300 trees, and 4 randomly
selected variables for each split. These hyperparameters were selected based on the model performance
on the OOB sample to derive the best performance.
As only 6% of our study cohort had a diagnosis of ADRD during follow-up, we used the Random
Over-Sampling Examples (ROSE) function from ROSE38,39 package in R to derive a synthetic balanced
sample to train the RF model. ROSE is a bootstrap-based technique that performs undersampling on the
majority class (those without ADRD) and oversampling of the minority class (those with ADRD) to
derive a balanced data (containing equal numbers of both classes). A new synthetic dataset is then created
using each observation’s neighborhood.40 We first divided our original dataset into a training and test
subsets and then used ROSE to generate a balanced synthetic training dataset to train our RF model. This
trained model was then tested and evaluated using the original and unaltered test subset to avoid
overestimation of the model performance. We used area under the ROC curve (AUROC) metric to
evaluate the performance of our final RF model, as this metric remains unaffected by re-balancing the
data.41 We used mean decrease in GINI index to identify the most important predictors of ADRD using
RF.
We also used partial dependence plots (PDP)42, an interpretable machine learning technique, to
examine the marginal contribution of each predictor to the model output. This allowed us to examine the
type of relationship (linear or non-linear) of a predictor with ADRD risk. To identify the joint effect of
duration of NSAID use and other variables on the risk of ADRD, we built bivariate PDPs. These plots
allowed us to identify the subgroups of patients that may be likely to receive benefit or harm from longterm NSAID use as it relates to ADRD risk.
Results
Our study cohort comprised 16,496 baseline ADRD–free older adults with OA. ADRD was
diagnosed in 6.4% (n = 1,048) of cohort elders during the follow-up period. Overall, a significantly higher
percentage women (6.6% vs 5.9% men), or those who were diagnosed with delirium (20.4% vs 5.8%),
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anxiety disorders (8.6% vs 6.1%), depression (10.4% vs 5.6%), stroke (12.7% vs 6.0%), ischemic heart
disease (8.8% vs 5.9%), congestive heart failure (11.9% vs 6.1%), or atherosclerosis (9.8% vs 6.2%), or
who met the criteria for polypharmacy (6.9% vs 5.6%) at baseline were diagnosed with ADRD compared
to those without these characteristics. On the other hand, a significantly lower percentage of those with
NSAID use (5.2% vs 6.9%) or those who were obese (4.1% vs 6.8%) were diagnosed with ADRD than
those without these characteristics. The mean age of those diagnosed with ADRD was significantly higher
than those without ADRD (80.4 vs 75.2 years). Additionally, approximately 30% of older adults had
prescription NSAID use at baseline. However, the mean duration of NSAID use in those diagnosed with
ADRD did not significantly differ from that of undiagnosed individuals (35.4 days vs 40.6 days).
The final RF model had an OOB error rate of 19.9% to predict ADRD risk. The model achieved
an accuracy of 69.7%, sensitivity of 63.5%, and specificity of 70.1% using test data to predict ADRD.
The AUROC for the final model was 0.72 (95% CI- 0.69-0.76). The top 10 predictors of ADRD from the
final RF model are presented in figure 1. These were: age, NSAID duration, delirium, polypharmacy, OArelated pain, sex, hyperlipidemia, depression, diabetes, and COPD. Other than age, NSAID duration and
delirium, all other predictors had almost similar importance scores albeit higher than the other less
important predictors not shown in the figure.
Partial dependence plots (PDPs) showing the marginal contribution of the top 5 predictors of
ADRD from the RF model are presented in Figure 2. The y-axis in all graphs from Figure 2 presents log
of the fraction of the votes from all trees in the RF indicating the presence of ADRD. A positive value on
the y-axis would suggest that the presence of ADRD is more likely and vice versa. Thus, the PDP for age
shows that the likelihood of a person being classified as having ADRD increased with age and was much
higher among individuals older than 80 years. On the other hand, duration of NSAID use had a non-linear
association to ADRD risk, with shorter durations (<30 days) predicting lower likelihood of incident
ADRD and longer durations (>30 days) predicting higher or similar risk for ADRD depending on the
length of such use. The PDPs for delirium and polypharmacy variables show that the presence of these
characteristics was associated with a higher likelihood of a person being classified as having ADRD.
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Notably, the absence of these characteristics made it less likely for a person to be classified as having
incident ADRD. Compared to the absence of OA-related pain, the presence of OA-related pain at baseline
was associated with a lower likelihood of being classified as ADRD .
To understand the joint effect of NSAID duration and other characteristic on the risk of ADRD,
we used bivariate PDPs. Figures 3 to 5 display the results from this analysis. As illustrated in these plots,
NSAID duration had differential effect on ADRD risk depending on the interacting variable. For example,
longer duration of NSAID use (>200 days) was associated with a higher risk of ADRD in females and in
those individuals with OA-related pain, sleep disorders, hyperlipidemia, hypertension, or atherosclerosis
(Figure 3). On the other hand, any duration of NSAID use was associated with a lower risk of ADRD risk
in individuals with stroke, delirium, depression, or anxiety disorders (Figure 4). However, the joint effect
of variables like age and congestive heart failure with duration of NSAID use on ADRD risk was not
clear (Figure 5).
Discussion
Using real-world data from a cohort of older adults with OA and RF for classification, our study
identified the leading predictors of incident ADRD in older adults with diagnosed OA. In our study
cohort, 6.4% had incident ADRD which is consistent with another study1 focusing on older adults. While
one other study45 using Optum data predicted prevalent ADRD with logistic regression (AUC = 0.63), it
focused on a very broad definition of ADRD and was not restricted to older adults with OA.
We identified age, NSAID duration, delirium, polypharmacy, and OA-related pain as the top 5
predictors of incident ADRD in our study cohort. All of these factors have been shown to be associated
with a higher risk of ADRD in other studies. As there are no published studies on the predictors of ADRD
among individuals with OA, we compare our findings to the studies that included individuals with and
without OA. We observed that age was the leading predictor of ADRD in older adults with OA. This is
not surprising given that older age is widely recognized as the strongest predictor of ADRD.46,47 While
age is not a modifiable factor, results from other studies48,49 indicate that almost half of the patients with
dementia remain undiagnosed. Results from the PDP in our study indicate that the risk of ADRD is much
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higher in those aged 80 and older. Those individuals with older age and one or more of the other leading
predictors associated with a higher risk of ADRD should be closely monitored for dementia-like
symptoms. Moreover, the bivariate PDPs showed that the effect of NSAID duration on ADRD risk did
not vary with age.
Although ADRD and delirium have a bidirectional relationship, delirium is increasingly
recognized as an independent risk factor for incident ADRD.50,51 The study by Davis et al51, using data
from older adults aged 85 and over followed for up to 10 years, reported that delirium increased the risk
of incident dementia by 8-fold. A comprehensive literature review of eight studies by Fong et al50
reported similar findings. While the exact pathophysiologic relationship between delirium and dementia is
unknown, several mechanisms have been hypothesized. It is thought that factors such as hypoxia, stroke,
certain medications, and metabolic abnormalities associated with delirium may contribute to adverse
structural and functional changes in the brain that may, in turn, increase the risk for dementia.52,53 Based
on the combined evidence from our study and published literature, studies are needed to identify effective
interventions for reducing the risk for delirium in older adults. The results of the bivariate PDPs showed
that any length of NSAID use may be beneficial in decreasing the risk of ADRD in older adults with OA.
However, prospective studies are needed to confirm this finding in this subgroup of patients.
Moreover, in our study cohort, we observed that individuals with OA-related pain were less likely
to be diagnosed with ADRD. In contrast, findings from a recent retrospective cohort study1 of Medicare
beneficiaries indicated significantly elevated risk for incident ADRD in those with OA and pain at
baseline. The discrepancy in findings may reflect differences in study populations (notably, the latter
study was not restricted to adults with OA), in the reference group (OA without pain vs. no OA and no
pain), and in the measurement of pain (self-reported hip/knee pain versus diagnosed, back, neck, joint, or
neuropathic pain). Moreover, we found that NSAID use interacted very strongly with OA-related pain
variable. Specifically, in individuals with OA-related pain, longer NSAID duration was associated with an
increased risk of ADRD compared to no NSAID use. It is likely that individuals with greater pain are
more likely to use NSAIDs. Moreover, the higher risk of ADRD with longer NSAID duration that we
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observed in our study could be mainly driven by pain and related inflammation. However, this interplay
between OA-related joint/hip pain and NSAID-related increase in the risk of ADRD needs to be further
evaluated.
A novel finding in our study was the complex relationship of NSAID duration, a leading predictor
in our study cohort, to ADRD risk. Apart from the variables mentioned above, we observed that many
other variables affected the relationship between duration of NSAID use and ADRD risk. While a recent
meta-analysis54 of observational studies along with some other epidemiological studies25,26,55 concluded
that NSAID use was associated with a reduced risk of ADRD, some of the clinical trials28,29,56 failed to
show such benefit. One possible reason for these conflicting results could be the way they defined NSAID
exposure. While some studies only focused on specific NSAIDs (e.g. diclofenac or etoricoxib), some
others considered even a single day of NSAID use in their exposure definition. Additionally, the clinical
characteristics of patients included in these studies were different, with none specifically evaluating the
relationship of NSAID use and ADRD in older adults with OA.
Our study provides important findings on the link between leading predictors of ADRD with
special emphasis on NSAID use. However, our study has several limitations. Since this is an
observational retrospective study, we cannot infer causality. We did not have information on the severity
and duration of OA, both of which may affect the NSAID use and risk for ADRD. We also did not have
any information on several lifestyle factors including physical activity and functional limitations which
have been shown to affect the risk of ADRD.58,59 Additionally, the claims data did not include any
information on certain genetic risk factor, for example, apolipoprotein E (APOE). Specifically, APOE ε4
allele has been shown to increase the risk of ADRD and has also been more amenable to risk reduction
with NSADs.26,60 The health insurance claims data also lacked information on over-the-counter (OTC)
NSAID use, smoking, sleep, and socioeconomic status. Our study also did not include information on
NSAID dose and prior use. However, a previous study26 did not find an association between these factors
and the risk for ADRD. Another limitation of our study could be a shorter follow-up time of two years for
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a slow and insidious condition like ADRD. Prospective studies with longer follow-up durations are
warranted.
Conclusion
NSAID duration, along with age, delirium, polypharmacy, and OA-related pain were the top five
predictors of incident ADRD in this cohort of older adults with OA. The relationship of NSAID duration
with ADRD risk was complex and influenced by multiple factors, suggesting that this association cannot
be adequately captured with a single aggregate metric. We also observed heterogeneous effects of NSAID
duration on incident ADRD risk. This finding suggests that only some subgroups of individuals may be
able to benefit from NSAID use to reduce the risk of ADRD. Future prospective cohort studies with
longer duration of follow-up and comprehensive information on potential risk factors are needed to
confirm our findings and further investigate the relationship between NSAIDs duration and incident
ADRD in older adults with OA.

Figures and Tables
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Table 4.1. Selected Baseline Sample Characteristics by ADRD;
Older Adults with Osteoarthritis (n = 16,496), 2014-2016
Dementia
No Dementia
Variable
N
%
N
% p-value
All
1,048
6.4 15,448 93.6
Age
<0.001
65-69
78
2.0
3,739 98.0
70-74
135
3.1
4,257 96.9
75-79
199
5.9
3,172 94.1
80 and over
636 12.9
4,280 87.1
Sex
<0.084
Female
731
6.6 10,376 93.4
Male
317
5.9
5,072 94.1
NSAID Use
<0.001
Yes
258
5.2
4739 94.8
No
790
6.9 10709 93.1
Delirium
<0.001
Yes
127 20.4
496 79.6
No
921
5.8 14952 94.2
Sleep disorders
0.187
Yes
184
6.9
2473 93.1
No
864
6.2 12975 93.8
OA-related pain
0.251
Yes
679
6.2 10276 93.8
No
369
6.7
5172 93.3
Anxiety disorders
<0.001
Yes
165
8.6
1753 91.4
No
883
6.1 13695 93.9
Substance abuse disorder
0.849
Yes
74
6.5
1067 93.5
No
974
6.3 14381 93.7
Depression
<0.001
Yes
265 10.4
2283 89.6
No
783
5.6 13165 94.4
Stroke
<0.001
Yes
96 12.7
658 87.3
No
952
6.0 14790 94.0
IHD
<0.001
Yes
243
8.8
2534 91.2
No
805
5.9 12914 94.1
Congestive heart failure
<0.001
Yes
79 11.9
586 88.1
No
969
6.1 14862 93.9
Polypharmacy
0.001
Yes
672
6.9
9121 93.1
No
376
5.6
6327 94.4
Obesity
<0.001
Yes
124
4.1
2875 95.9
No
924
6.8 12573 93.2
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Table 4.1. Selected Baseline Sample Characteristics by ADRD;
Older Adults with Osteoarthritis (n = 16,496), 2014-2016
Dementia
No Dementia
Variable
N
%
N
% p-value
Atherosclerosis
<0.001
Yes
78
9.8
717 90.2
No
970
6.2 14731 93.8
Mean and Standard Deviation (SD) for Continuous Variables
Mean SD Mean SD p-value
Age
80.4
6.3
75.2
6.6 <0.001
Duration of NSAID use (days)
35.4 88.1
40.6 91.7
0.061
Note: The sample includes patients from De-identified Optum Clinformatics Data Mart.
ADRD- Alzheimer's disease and related dementia; IHD- ischemic heart disease; NSAID- non-steroidal antiinflammatory drugs; OA- osteoarthritis
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Figure 4.1 Top 10 Predictors of ADRD Using Variable Importance Plot from Random Forest
Note: The sample includes 16,496 older adults with osteoarthritis from De-identified Optum Clinformatics Data
Mart (2014-2016)
ADRD- Alzheimer’s disease and related dementia; COPD- chronic obstructive pulmonary disease; NSAIDnonsteroidal anti-inflammatory drugs; OA-osteoarthritis
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Figure 4.2 Univariate Partial Dependence Plots for Top 5 Predictors of ADRD from Random Forest
Note: The sample includes 16,496 older adults with osteoarthritis from De-identified Optum Clinformatics Data
Mart (2014-2016)
ADRD- Alzheimer’s disease and related dementia; NSAID- nonsteroidal anti-inflammatory drugs; OAosteoarthritis
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Figure 4.3 Variables with a Higher Risk of ADRD With Longer Duration of NSAID Use Based on
Bivariate Partial Dependence Plots
Note: The sample includes 16,496 older adults with osteoarthritis from De-identified Optum Clinformatics Data
Mart (2014-2016)

The y-axis presents log of the fraction of the votes from all trees in the random forest indicating the
presence of ADRD. The x-axis presents duration of NSAID use in days and the values of the interacting
variable.
ADRD- Alzheimer’s disease and related dementia; NSAID- nonsteroidal anti-inflammatory drugs; OA-osteoarthritis
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Figure 4.4 Variables with a Lower Risk of ADRD With Longer Duration of NSAID Use Based on
Bivariate Partial Dependence Plots
Note: The sample includes 16,496 older adults with osteoarthritis from De-identified Optum Clinformatics Data
Mart (2014-2016)

The y-axis presents log of the fraction of the votes from all trees in the random forest indicating the
presence of ADRD. The x-axis presents duration of NSAID use in days and the values of the interacting
variable.
ADRD- Alzheimer’s disease and related dementia; NSAID- nonsteroidal anti-inflammatory drugs
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Figure 4.5 Variables with No Change in Risk of ADRD With Longer Duration of NSAID Use Based
on Bivariate Partial Dependence Plots
Note: The sample includes 16,496 older adults with osteoarthritis from De-identified Optum Clinformatics Data
Mart (2014-2016)

The y-axis presents log of the fraction of the votes from all trees in the random forest indicating the
presence of ADRD. The x-axis presents duration of NSAID use in days and the values of the interacting
variable.
ADRD- Alzheimer’s disease and related dementia; CHF- congestive heart failure; NSAID- nonsteroidal antiinflammatory drugs
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Chapter 5
5 Summary of Findings, Discussion and Implications
In a series of “first”, this dissertation examined complex health management issues in older adults
with OA. This patient population is important to study because of the high prevalence of OA, the
significant clinical, humanistic, and economic burden associated with OA, and challenges in the
management of OA.6,19 A common theme of this dissertation revolves around the complexity in the
pharmacological management of OA. As there is no cure or disease-modifying agents for OA, the main
goal of OA management is to provide symptom relief to slow the progression of the disease and maintain
functional ability of the patients. The pharmacological management of OA consists of treating pain,
which is the hallmark symptom of OA and a leading cause of disability.21 A vast majority of older adults
with OA report pain and are prescribed opioids or NSAIDs to control pain.39,40 In the current opioid
epidemic crisis with regulatory controls on opioid prescriptions212, OA patients may need to increasingly
rely on prescription NSAIDs for pain relief. The pain management of OA with NSAIDs creates
complexity in medical decision-making because NSAIDs used for pain relief can lead to adverse
cardiovascular (CV) and gastrointestinal (GI) effects.28 While NSAIDs have unfavorable drug-disease
interactions, they may also have a beneficial drug-disease interaction. For example, the cyclooxygenase
inhibition (COX) inhibition by NSAIDs has been shown to increase the risk of CV and GI adverse events
(AEs) due to an imbalance in prostaglandins and thromboxanes.28,213 The resulting decrease in these same
molecules has been shown to decrease neuroinflammation and therefore can reduce the risk of
neurodegenerative conditions such as ADRD.35,48 The development of ADRD is generally insidious with
significant negative health consequences for patients, caregivers and families, payers, policy makers, and
the society as a whole. With effective disease-modifying treatments that ADRD is still lacking, research is
shifting increasingly to prevention. ADRD is influenced by a complex interplay of modifiable and nonmodifiable factors. The modifiable factors for ADRD include medications such as statins and NSAIDs
that are associated with a reduced risk for ADRD.178,179 Recent studies also suggest that modifiable
clinical care-related factors such as polypharmacy may also increase the risk of ADRD.214
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Therefore, this dissertation focused on three-related studies that sought to: 1) identify “high-risk”
patients as defined by those with either CV or GI disorders (CV-GID) to inform pharmacological
management of OA; 2) whether the high-risk patients continue to be prescribed NSAIDs, that may be
considered inappropriate, and 3) what is the association of NSAIDs to ADRD risk?
For all 3 aims, machine learning algorithms were selected because of their better predictive
accuracy, ability to identify complex interactions among variables and handle multicollinearity.67,215
These techniques are also free of any assumptions about the underlying distributions of the variables. In
these studies, we used CVLR, and random forest (RF)76 or eXtreme Gradient Boosting (XGBoost)72
classifiers. In our analysis comparing the performance of the machine learning classifiers to multivariable
logistic regression, we found that both models performed almost similar in terms of area under the
receiver-operating curve (AUROC) metric. The only metric on which the machine learning algorithms
were better than logistic regression was sensitivity. While multiple studies73–75 have found RF and
XGBoost classifiers to be better than traditional statistical methods, it is likely that such distinction is hard
to make using structured data from a single source which lacks important clinical variables like laboratory
measurements. Typically, machine learning algorithms are considered to be “black box” because they
focus only on prediction and on predictor-outcome relationships. To understand the association of leading
predictors to the outcomes, we “unboxed” these algorithms with the use of interpretable machine learning
(IML) techniques.68–70 We also used IML to study the interactions between the predictors of interest and
their effect on the model predictions.
Summary of findings
Predictors of CV-GID
Our analyses revealed that CV-GID was very common among older adults with OA. Our results
indicated that polypharmacy and the fragmentation of care index (FCI) were the leading predictors of CVGID in our study cohort. These two variables often indicate a high prevalence of multimorbid conditions
and visits to multiple providers. Our results suggest that reducing multimorbidity may be able to reduce
care fragmentation and polypharmacy in this group of individuals. It is likely that multimorbidity can lead
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to a “cascade” of effects such as polypharmacy, fragmented care, which in-turn may lead to “prescribing
cascades” with more medications being prescribed to treat the AEs related to another medication.216 We
also found that UTI was a predictor of CV-GID.
Implications:
Our results from study 1 suggest that investing in interventions that can reduce the risk for multimorbidity
may go a long way in reducing the risk for care fragmentation and polypharmacy and ultimately CV-GID.
Additionally, our study revealed a novel area of investigation by uncovering a relationship between
urinary tract infection (UTI) and CV-GID.118,119 Infections often trigger an inflammatory reaction in the
body, which increases white cell production and increase the stickiness of platelets leading to formation
of clots that block the flow of blood to the heart.118 Our study findings suggest that clinicians may need to
monitor adults with OA with infectious diseases to reduce the risk of CVD.
Predictors of inappropriate NSAID use
From our study 1, we observed that many adults with OA can be considered as “high-risk”
patients for NSAID-related adverse events. Despite several clinical guidelines suggesting the use of
NSAIDs for the shortest duration and lowest possible dose, several studies conducted outside the US have
reported that high prevalence of NSAID use (i.e. inappropriate NSAID use) among “high-risk” adults.
Using XGBoost, we found that adults at high CV or high GI risk had inappropriate NSAID use.
Moreover, baseline NSAID use was the top predictor of inappropriate NSAID use.
Implications:
Our study contributed to the development of a composite measure of “inappropriate” NSAID use
based on existing guidelines, published sources, and clinical input from study clinicians. Our study
findings have implications for clinicians as well as payers. Due to the ongoing opioid epidemic,
physicians and patients may be forced to increasingly rely on NSAIDs for pain relief. Our results show
that clinicians should ensure that NSAIDs used for short-term pain relief are not being used for long-term
to avoid potential AEs. Our results also showed that individuals using non-pharmacological treatments
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like physical therapy were less likely to have inappropriate NSAID use. An exploration of the effect of
other non-pharmacological interventions on inappropriate NSAID use is warranted.
Predictors of ADRD
Due to NSAIDs’ effect on reducing inflammation and the link between inflammation and an
increased risk for ADRD, we also evaluated whether NSAID use was associated with a reduced risk of
ADRD in older adults with OA. Using random forest and IML techniques, we observed that duration of
NSAID use was among the top 5 predictors of ADRD. We also observed that the relationship between
NSAID duration and ADRD risk was non-linear and complex with shorter duration providing some
protection against ADRD but no protection or even harm at longer duration. Further exploration of the
interactions of NSAID with other variables showed that the relationship between NSAID duration and
ADRD risk varied in different subgroups of patients. We observed that the longer duration of NSAID use
was associated with a lower likelihood of ADRD risk in older adults with OA and mental health
conditions like delirium, anxiety, and depression. This finding suggests that NSAIDs may have a role to
play in inflammation-associated conditions.
Implications
Our results show that the relationship between NSAID use and ADRD risk is complex and may not be
uncovered using a heterogeneous group of individuals. With the help of IML, we observed that NSAID
duration affected the risk for ADRD in a non-uniform fashion in individuals with different comorbidities.
The only group of individuals seemed to benefit from longer duration of NSAID use were those with
mental health conditions including delirium, anxiety, and depression. As we move towards personalized
medicine, identifying such characteristics which may reduce the risk of ADRD can be very helpful. Our
results also showed that delirium was one of the top predictors of ADRD. As up to 30% risk of delirium
can be reduced with interventions that manage risk factors of delirium, identifying the individuals that can
benefit the most from such interventions should be a key priority in reducing the risk of incident
ADRD.217
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Strengths
Our study has many strengths. The use of real-world data from health insurance claims allowed
us to generate results applicable to routine clinical practice. With the use of these data, we had access to
and were able to include a comprehensive list of variables related to OA care and demographics in our
study. We used robust machine learning methods which allowed us to not only identify the leading
predictors but also allowed us to uncover interactions among variables. With the help of IML, we were
able to examine the relationship between the leading predictors and the target variable. Our study focused
on older adults with OA, a population not studied before for a similar research but at a higher risk of
several chronic conditions including CV-GID and ADRD. This is also the first study to examine the
leading predictors of inappropriate NSAID use and CV-GID in this population.
Limitations
As this is a retrospective observational study, we cannot infer causality. Health insurance claims
data do not provide information on over-the-counter medication use, lifestyle factors (e.g. physical
activity), disease severity, and pain severity. Results using data from older adults with Medicare
Advantage plans may not be generalizable to all older adults with OA in the US. The prescription fills
used to identify study medications may not actually indicate their use by patients. Our study may also
have suffered from misclassification bias if those without any claims for the conditions studied did not
have an inpatient or outpatient claim. We cannot rule out the possibility of selection bias in our study.
Suggestions for future research
Prospective cohort studies are needed to examine the leading predictors of incident CV-GID in
older adults with OA. Studies are also warranted to see whether interventions that improve care
coordination and decrease polypharmacy lead to a decrease in CV-GID. An evaluation of nonpharmacological interventions to reduce the risk of inappropriate NSAID use is also needed. Prospective
cohort studies in older adults with mental health conditions including delirium, anxiety, or depression are
needed to confirm whether NSAID use reduces the risk for ADRD.
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Appendices
Table A2.1 Diagnosis Codes Used to Identify Cardiovascular and Gastrointestinal Disorders (CVGID)
Condition
ICD-9 Codes
ICD-10 Codes
Angina
413.x
I20.x
Myocardial infarction
410.xx
I21.xx-I23.x
Other ischemic heart disease 411.xx
I24.x, I25.xx
Stroke
430.x, 431.x, 433.x-436.x, 362.3
I60.x, I61.x, I63.x, I64.x,
H34.1, G45.x
Congestive heart failure
398.91, 402.x1, 402.x3, 404.x1,
I50.xx
404.x3, 422.90, 425.4, 425.9, 428.xx
Dyspepsia
GERD
Uncomplicated PUD

536.8
530.11, 530.81
531.3, 531.7, 531.9, 532.3, 532.7,
532.9, 533.3, 533.7, 533.9, 534.3,
534.7, 534.9

K30
K21.0, K21.9
K25.3, K25.7, K25.9, K26.3,
K26.7, K26.9, K27.3, K27.7,
K27.9, K28.3, K28.7, K28.9

Complicated PUD

531, 531.1, 531.2, 531.4, 531.5,
531.6, 532, 532.1, 532.2, 532.4,
532.5, 532.6, 533, 533.1, 533.2,
533.4, 533.5, 533.6, 534, 534.1,
534.2, 534.4, 534.5, 534.6, 535.01,
535.11, 535.21, 535.31, 535.41,
535.51, 535.61, 578, 578.1, 578.9

K25.0-K25.6, K26.1-K26.2,
K26.4-K26.6, K27.1-27.2,
K27.4-K27.6, K28.1-28.2,
K28.4-K28.6, K29.01, K29.21,
K29.41, K29.51, K29.61,
K29.71, K29.81, K29.91,
K92.0-92.2

Table A3.1 Diagnosis Codes Used to Identify Gastrointestinal and Cardiovascular Risk Factors
Disease or Condition
ICD-10 codes
150,218
Complicated peptic ulcer disease
K25.0-K25.6, K26.1-K26.2, K26.4-K26.6, K27.127.2, K27.4-K27.6, K28.1-28.2, K28.4-K28.6,
K29.01, K29.21, K29.41, K29.51, K29.61,
K29.71, K29.81, K29.91, K92.0-92.2
Uncomplicated peptic ulcer disease150,218
K25.3, K25.7, K25.9, K26.3, K26.7, K26.9,
K27.3, K27.7, K27.9, K28.3, K28.7, K28.9,
Z87.11
Dyspepsia219
K30
Gastroesophageal reflux disorder219
K21.0, K21.9
220
Angina
I20.0, I20.1, I20.8, I20.9
Stroke221
I60.x, I61.x, I63.x, I64.x, H34.1, G45.x
Myocardial infarction219
I21.09, I21.11, I21.19, I21.3, I21.4, I21.9, I21.A9,
I25.2
222
Congestive heart failure
I50.xx
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